Seton Hall University

eRepository @ Seton Hall
Seton Hall University Dissertations and Theses
(ETDs)

Seton Hall University Dissertations and Theses

Spring 5-15-2017

Diversity Oriented Synthesis, Characterization and
Anti-Cancer Activity of Killer Peptide Nucleolipid
Bioconjugates
Niki K. Rana
niki.rana@student.shu.edu

Follow this and additional works at: https://scholarship.shu.edu/dissertations
Part of the Amino Acids, Peptides, and Proteins Commons, Biochemistry, Biophysics, and
Structural Biology Commons, Biodiversity Commons, Cancer Biology Commons, Carbohydrates
Commons, Inorganic Chemicals Commons, Lipids Commons, Macromolecular Substances
Commons, Nucleic Acids, Nucleotides, and Nucleosides Commons, Organic Chemicals Commons,
and the Polycyclic Compounds Commons
Recommended Citation
Rana, Niki K., "Diversity Oriented Synthesis, Characterization and Anti-Cancer Activity of Killer Peptide Nucleolipid Bioconjugates"
(2017). Seton Hall University Dissertations and Theses (ETDs). 2281.
https://scholarship.shu.edu/dissertations/2281

DIVERSITY ORIENTED SYNTHESIS, CHARACTERIZATION AND ANTI-CANCER
ACTIVITY OF KILLER PEPTIDE NUCLEOLIPID BIOCONJUGATES

A thesis submitted to Seton Hall University in partial fulfillment of the requirements for the
degree of Doctor of Philosophy

By

Niki K. Rana

May 2017

Department of Chemistry and Biochemistry
Seton Hall University
South Orange, NJ, USA

©

Copyright 2017 (Niki K. Rana)

ii

DISSERTATION COMMITTEE APPROVALS

We certify that we read this thesis and in our opinion, it is sufficient in scientific scope and
quality as a dissertation for the degree of Doctor in Philosophy.

APPROVED BY:

David Sabatino, Ph.D.
Research Mentor, Seton Hall University

eader, Member of Dissertation Committee,
Seton Hall University

I~'kc,~'
Reader, Member of Dissertation Committee,
Seton Hall University

Cecilia Marzabadi, Ph.D.
Chair, Department of Chemistry and Biochemistry,
Seton Hall University
iii

I dedicate this thesis to
my parents, Kamleshkumar, Nayanaben, and my sister, Urvi,
for their constant support and unconditional love.

iv

ABSTRACT

The killer peptide sequence D-(KLAKLAK)2 has been originally designed and developed
as an antibacterial agent. Despite having excellent cytotoxicity towards bacteria, this sequence
maintains low cell cytotoxity in malignant mammalian cell types such as cancer. The chemical
basis for its selectivity has been attributed to its poly(cationic) amphiphilic nature, which facilitates
cell permeability across the negatively charged bacterial membrane, but with limited permeability
across the zwitterionic membrane of mammalian cells. The positively charged D-(KLAKLAK)2
sequence has been found to accumulate on the surface of the mitochondria causing dissipation of
the negatively charged mitochondrial membrane potential. This charge disruption results in
membrane lysis and the secretion of cell death markers that ultimately lead to programmed cell
death. In order to overcome the limited activity of the D-(KLAKLAK)2 sequence in malignant
tumor cell types, we proposed that chemically robust and structurally pre-organized amphiphilic
nucleolipids would function to enhance cell permeability and mitochondria localization in tumors,
resulting in potent and long-lasting anti-cancer effects. In this study, thymidine-derived
nucleolipids were rationally designed to contain 3’-lipid appendages and a reactive 5’-carboxy
group. A diversity oriented synthesis approach featuring a reductive amination procedure was
developed for making a small library of amphiphilic nucleolipids. Solid phase bioconjugation
coupled the nucleolipids with the pro-apoptotic D-(KLAKLAK)2 sequence for exploring structureactivity relationships. The peptide nucleolipid conjugates were found to self-assemble into
amphiphilic nanoparticle formulations that promoted anti-cancer activity in a selected panel of
cancer cells. This thesis will serve to highlight the most important findings towards the
development of peptide-nucleolipid conjugates that effectively serve as potent anti-cancer agents.
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CHAPTER 1. BIO-ACTIVE PEPTIDES: AN OVERVIEW OF THEIR
STRUCTURE-FUNCTION
RELATIONSHIP
FOR
ANTI-CANCER
ACTIVITY

1.1 ABSTRACT
Biologically active peptides exhibit a variety of beneficial effects, including anti-proliferative,
antioxidant, anti-microtubule, and antibacterial properties. Their isolation from natural sources e.g.
plant and marine sources, including algae and cyanobacteria have led to the development of many
antibiotic and anti-cancer drugs. Vancomycin is among the most famous examples. Bioactive
peptides have also been isolated as secondary metabolites derived from sponges, ascidians,
tunicates and mollusks. For example, protein hydrolysates derived from the enzymatic digestion
of aquatic and marine by-products are an important source of bioactive peptides. These exhibit
antioxidant, antimicrobial activities and cytotoxic effects on malignant mammalian cancer types
such as HeLa, AGS, and DLD-1 cells. Key to their biological activity are various amino acid
residues that may be naturally occurring or modified, in addition to the incorporation of ions, small
molecules and transition metal ligands that can tailor the structure-function properties of the
peptides. An important class of biologically active peptides belong to the amphiphilic, -helical
cell penetrating peptides (CPPs). CPPs internalize within cells and traffic within endosomes until
endosomal escape contributes to their delivery to various organelles. A common subcellular target
for the positively charged CPPs is the negatively charged membrane surface of the mitochondria.
Upon binding, depolarization of the negatively charged (-180 mV) mitochondrial membrane
results in a loss of mitochondrial membrane integrity that stimulates the release of mitochondrial
contents into the cytoplasm. The release of cell death effectors from the mitochondria, including
cytochrome c, second mitochondrial derived activator of caspase and the apoptosis-inducing factor

1

(AIF) ultimately trigger programmed cell death. These desirable structure-function properties has
led to the development of a new class of mitochondria penetrating peptides (MPPs) that exhibit
potent activity against chronic diseases such as cancer.

1.2 INTRODUCTION
Short bioactive peptide sequences may exhibit efficient cellular uptake in mammalian cell
types. These cell-penetrating peptides (CPPs) tend to have distinct structure-function properties.
They include amphiphilic primary sequence compositions that typically include hydrophobic and
positively charged amino acid residues. Moreover, the secondary structures of CPPs tends to be
-helical in nature. The amphiphilic peptide sequence has been shown to contribute to membrane
affinity and translocation activity. Moreover, the -helical peptide structure that has been found
in many membrane spanning pore proteins has also been correlated as a secondary structure motif
conducive to membrane transport and intracellular localization of soluble analytes [1]. A variety
of cell translocation mechanisms have been attributed to the CPPs, including receptor and nonreceptor mediated endocytosis, micro- and pinocytosis which encapsulates the peptides in
membrane-bound endosomes for intracellular trafficking and release at the targeted site for activity
[2]. A common target for the CPPs is the mitochondrion. The mitochondrion is a key organelle
that performs essential cellular functions and plays pivotal roles in regulating cellular metabolism,
senescence and survival. Thus, the mitochondria represents an entry point of interest for organellespecific delivery of effector molecules used to treat metabolic, degenerative and hyperproliferative
diseases [3]. In spite of their utility, mitochondria-targeting drugs remain hampered by a variety
of side effects that limit their potential clinical utility. Therefore, the discovery of new drug-like
molecules used to target the mitochondria in diseased cells and tissues is currently an urgent, unmet need. Towards this end, a series of short, amphiphilic peptides that penetrate the plasma
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membrane and localize within the mitochondria for biological activity have served as promising
leads. For example, the Tat peptide, (Figure 1.1) derived from the HIV transactivator protein is
considered one of the first representative examples of a mitochondria-penetrating peptide (MPP)
[4].

Figure 1.1. Primary sequence of the HIV-Tat peptide (48-60), GRKKRRQRRRGYKC, as a
representative mitochondria-penetrating peptide. Figure adapted from reference Green, M.,
Loeweinstein, M. Cell, 1988, 55, 1179 – 1188.
Once internalized within cells, MPPs accumulate on the surface of the mitochondria and
induce depolarization of the mitochondrial membrane. This depolarization commonly results in
cell apoptosis [5]. For example, the depolarization and disruption of the mitochondrial membrane
results in the release of the cell death markers such as the apoptosis inducing factor (AIF).
Additionally, Ca2+ flux plays an important role for VDAC mediated calcium ion signaling. In
compromised cells, unregulated Ca2+ flux leads to the release of caspase co-factors needed for the
pro-apoptotic activity of the caspase enzymes. Similarly, the calcium signaling receptor- BCL-2 is
a class of proteins found exclusively on the cell surface of the mitochondria that regulates cell
death events [5]. The BCL-2 family of proteins constitutes a critical checkpoint in the apoptotic
cascade. BAX, BH3, BAK are also pro-apoptotic checkpoints functioning with BCL-2 at the
3

mitochondrial membrane [6]. In cells with damaged mitochondria, BCL-2 signaling triggers the
release of pro-apoptotic executors, including cytochrome c and reactive oxygen species. The
formation of reactive oxygen species (ROS) aberrantly oxidizes biological molecules, altering
their structure-function properties that ultimately impedes their normal cellular function [7]. Under
these so-called “stressed conditions” protein misfolding also occurs and the unfolded-protein
response (UPR) either rescues these proteins through chaperone activity or signals the release of
caspase enzymes as pro-apoptotic executors in the absence of protein salvaging. Taken altogether,
MPPs that serve to disrupt mitochondria structure and function can ultimately lead to programmed
cell death by a variety of cell death signaling pathways (Figure. 1.2).
In order to improve the structure-function properties of the MPPs, small molecule and
biological ligands that effectively target selected cell types and accumulate within the
mitochondria have been developed. Small molecule ligands such as triphenylphosphine (TPP) and
choline esters incorporated within MPPs improved their inner mitochondrial membrane (IMM)
localization properties. For the incorporation of IMM-specific biologicals, including
phospholipids, gramicidin S (GS)-based antioxidants have also improved activity, with the
concomitant delivery of nitroxide ROS scavengers into the cellular matrix [8]. Organometallic
complexes e.g. metalloporphyrin-MPP conjugates (Figure. 1.3), have also been developed as
antioxidants within the mitochondria [9]. For example, the Mn-porphyrin-peptide stimulated
superoxide dismutase (SOD) activity and decomposed peroxynitrite (ONOO-), effectively
scavenging NO-mediated apoptosis that resulted in increased cell viability in lipopolysaccharide
[10] (LPS) stimulated macrophages RAW 264.7 cells.
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Figure 1.2. Possible cell death pathways triggered by the mitochondrial-targeting peptide D(KLAKLAK)2. Figure adapted from Farsinejad, S.; Gheisary, Z.; Ebrahimi, S.; Mohammad, A.A.
Tumor Bio, 2015, 36, 5715-5725.

Short synthetic peptides that correspond to the BH3 pro-apoptotic effector domains e.g.
BIDBH3 peptide sequence: EDIIRNIARHLAQVGDSMDR and BIMBH3 peptide sequence:
MRPEIWIAQELRRIGDEFNA have also been designed and developed. These so-called “killer
peptides” initiate the cell death cascade either by activating pro-apoptotic members or by
counteracting anti-apoptotic members by displacing BH3 antagonists from their binding domains
[11]. These killer peptides have been shown to trigger cell death in Jurkat leukemic cells.
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Figure 1.3 Chemical structure of Mn-porphyrin modified with the mitochondria signaling peptide.
Figure adapted from reference: Asayama, S., Kawamura, E., Nagaoka, S., Kawakamli, H. Mol.
Pharm., 2005, 3, 468-470.

1.3 D-(KLAKLAK)2
ANTIMICROBIAL PEPTIDE:
CHARECTERIZATION AND BIOLOGICAL ACTIVITY.

SYNTHESIS,

The pro-apoptotic peptide D-(KLAKLAK)2 is an antimicrobial peptide having the ability
to internalize within bacteria and disrupt the mitochondrial membrane (Figure 1.4) [12]. The proapoptotic domain of the D-(KLAKLAK)2 sequence is amphiphilic in nature and composed of
hydrophobic leucine and alanine residues and with positively charged lysines. Moreover, in
aqueous media, the peptide was found to adopt an -helical secondary structure. These properties
were found to be contributive to the biological activity of the peptide sequence, which readily
penetrated the bacterial cell membrane. Inside cells, the peptide localized and disrupted the
mitochondria leading to the selective cell death in bacteria and to a much lesser extent in
mammalian cells. This selective activity is partly due to the higher affinity of the positively charged

6

D-(KLAKLAK)2 peptide to the negatively charged bacteria cell surface, but to a lesser extent to
the more neutral and hydrophobic composition of the mammalian cell surface [13].

Figure 1.4. Primary sequence of the antimicrobial D-(KLAKLAK)2 peptide at physiological
pH=7.4. Figure adapted from reference Javadpour, M.M.; Juban, M.M.; Lo, W.C.; Bishop, S.M.;
Alberty, J.B.; Cowell, S.M.; Becker, C.L.; McLaughlin, M.L. J. Med. Chem. 1996, 39, 31073113.
In order to improve the biological activity of the D-(KLAKLAK)2 peptide within malignant
mammalian cell types, cancer targeting peptides (CTP) or monoclonal antibodies have been
incorporated to target and internalize the killer peptide sequence in cancer cells. For example a
peptide comprised of a protein transduction domain (PTD), PTD-5, fused to an antimicrobial
peptide, D-(KLAKLAK)2 was able to trigger rapid apoptosis in a variety of cell lines in vitro. This
included the MCA205 murine fibrosarcomas, the human head and neck tumors. A multifunctional
theranostic nanoparticle has also been reported, where the CGKRK peptide provides the targeting
function that takes the nanoparticles to tumor vascular cells and into their mitochondria. The
nanoparticle uses the mitochondria-targeted D-(KLAKLAK)2 peptide as the drug and iron oxide
as a diagnostic component for MRI [14, 15].
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In this study, the D-(KLAKLAK)2 will be synthesized using the Fmoc-Solid Phase Peptide
Synthesis (Fmoc-SPPS) method [16]. Upon completion of the synthesis cycle, the crude peptide
will be analyzed and purified by reverse phase high performance liquid chromatography (RP
HPLC). Characterization studies will be performed by electrospray ionization mass spectrometry
(ESI MS) to confirm molecular weight identity. The biophysical and structural properties will be
respectively analyzed by a combination of ultraviolet-visible (UV-Vis) and circular dichroism
(CD) Spectroscopy. These structure-function relationships are important determinations for
elucidating the biological activity of the killer D-(KLAKLAK)2 peptide sequence and its
conjugates within malignant cancer cell types.
1.3.1 SYNTHESIS AND CHARACTERIZATION OF D-(KLAKLAK)2.
Solid phase peptide synthesis (SPPS) has been recognized as the most widely used
technique for making short and long chain peptide sequences with natural and unnatural amino
acids [17]. The use of an insoluble resin is key to this efficient method and provides a solid support
for growing peptide sequences following coupling and deprotection steps of Fmoc-protected
amino acids (Scheme 1.1).
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Scheme 1.1. Schematic diagram of the Fmoc-based solid phase peptide synthesis cycle. Synthesis
cycle based on Behrendt, R.; White, P.; Offer, J. J. Pept. Sci. 2016, 22, 4-27.

The SPPS method was first invented by Nobel laureate Bruce Merrifield following the
synthesis of the short peptide (LAGV) on polymer beads [18]. Since then, many short and long
peptide sequences, including our target, D-(KLAKLAK)2, have been synthesized for a wide range
of applications in biology, chemistry and in medicinal chemistry [17]. The careful selection of the
insoluble solid support (resin) is a crucial first step to a successful peptide synthesis strategy. The
Merrifield-based polystyrene resin was first used in the synthesis of short peptide sequences.
However, this solid support proved challenging for making lengthier, more hydrophobic peptides
that aggregated during the course of peptide synthesis limiting coupling and deprotection
efficiency. Consequently, new and improved resins, including the, TentaGel and NovaPEG resins
[19,20] modified the polystyrene support with polyethylene glycol (PEG), (Figure 1.5). The
incorporation of PEG improved the polar properties of the Merrifield resin, providing it with
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greater swelling capabilities in N,N-dimethylformamide (DMF), the solvent of choice for SPPS
[20]. In addition, a suitable linker is incorporated in between the resin and the peptide sequence.
The linkers are especially useful for anchoring amino acids onto the solid support for peptide
synthesis but also for modifying the C-terminus of the sequence. For example, the Rink amide
linker has been incorporated for the generation of C-terminal peptide amides whereas the Wang
resin incorporates a linker that affords C-terminal peptide acids (Figure 1.5) [21]. Moreover, these
linkers also facilitate the removal of the peptide sequence from the solid support, which is typically
accomplished using concentrated trifluoroacetic acid (TFA) as opposed to the toxic hydrogen
fluoride (HF) gas initially used for the removal of peptides from the Merrifield resin.

Figure 1.5. Solid supports and linkers for Fmoc-SPPS. Rink amide (RL) or Wang linked (WL)
polystyrene-divinylbenzene (PS-DVB) 1.1) Rink amide-linker polystyrene-graft-poly(ethylene
glycol) resin (Tenta Gel, 1.2) poly(ethylene glycol) (NovaPEG, 1.3) Wang resin linker with solid
support.
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Following the judicious selection of an insoluble polymer support, and removal of the
fluorenylmethoxycarbonyl (Fmoc) protecting group using piperidine as a base, the linker-bound
support is ready for peptide synthesis. The N- Fmoc amino acids require orthogonal protection of
side chain functional groups with TFA-labile protecting groups (e.g. Boc). A reactive coupling
reagent effects the efficient coupling of amino acids to the linker-bound solid support. This
coupling step typically functions to convert the C-terminal carboxylic acid to a reactive ester which
favors coupling to the amino (peptide amides) or hydroxyl (peptide acids) groups on the solid
support. Moreover, coupling reagents also facilitate the key peptide bond forming reactions
between the N-terminal peptide bound support and the C-terminal active ester of the coupling NFmoc amino acid. Many coupling reagents for SPPS have been reported, including the
carbodiimide-based couplings [22]. More reactive reagents for coupling have been developed to
shorten the coupling times of N-Fmoc amino acids. These are particularly based on the uronium
coupling reagents, such as,

O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate (HCTU) which worked particularly well in the solid phase synthesis of
challenging peptides with coupling times as short as 1 minute [23].
The coupling procedure is followed by an Fmoc deprotection step, in which a secondary
alkylamine is used to effect the elimination of the Fmoc group without concomitant epimerization
of the peptide-bound support. Towards this goal, dilute solutions of alkylamines (i.e. 20%
piperidine or 4-methylpiperidine in DMF, 10% piperidine in EtOH/NMP, 10:90 v/v, and
piperazine/DBU) have been used to effectively un-mask the N-terminal amino groups for FmocSPPS [24]. These steps have been incorporated within fully automated peptide synthesizers with
and without microwave heating for rapid and high yielding coupling and deprotection steps.
Following synthesis, cleavage of the peptide from the solid support and deprotection of side-chain
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protecting groups are typically accomplished with concentrated trifluoroacetic acid (TFA) with
minimal addition (<5%) of reaction scavengers (i.e. H2O, triethylsilane, phenol and anisole). These
conditions minimize side-product formation and improve yields of the crude peptide in solution
for analysis and purification by RP HPLC. The identities of the isolated peptides are then
confirmed by molecular weight analysis using ESI MS. With pure peptides in hand, structurefunction properties are then investigated by a combination of spectroscopy, microscopy and
chromatography for potential biological applications.
1.3.2 FMOC-SOLID PHASE PEPTIDE SYNTHESIS OF THE D-(KLAKLAK)2
SEQUENCE
The goal of this study was to synthesize the antimicrobial killer peptide sequence D(KLAKLAK)2 by Fmoc-SPPS. Synthesis of this cationic peptide required the use of the PEGylated
ChemMatrix Rink amide resin with a loading capacity of 0.47 mmol/g. A quantity of resin (300
mg) was used for a 0.1 mmol scale peptide synthesis that was anticipated to yield ~30-50 mg of
the desired peptide sequence, sufficient for our structure-function relationship studies. Peptide
synthesis was conducted either in a semi-automated PSI 200C Peptide Synthesizer (Fairfield, NJ)
or within plastic PolyPrep cartridges. The resin was initially swollen in DMF and the addition of
Fmoc-amino acids (3eq.), HCTU as coupling reagent (3eq.), NMM as base (6 eq.) and DMF as
solvent (4-6 mL) were added to the resin to initiate the coupling reactions (Scheme 1.2). Typically,
HCTU mediated coupling reactions of Fmoc-amino acids reach completion in 20-30 minutes at
room temperature, while elevated temperatures (50-60 oC) and microwave irradiation allows for
much faster reaction times, on the order of 2-5 min [25]. Coupling reactions for the D(KLAKLAK)2 sequence conducted at room temperature in order to minimize the likelihood of
epimerization and side reactions at elevated temperatures [26]. Following coupling of Fmoc amino
acids, deprotection of the N-terminal of Fmoc group was accomplished using basic piperidine in
12

DMF (20% piperidine in DMF, 4 mL). Complete Fmoc deprotection typically required successive
additions of the piperidine reaction mixture. An initial treatment for 3-5 min removes most of the
Fmoc group while a second, longer reaction for about 15 min was used to remove the remaining
quantities of protecting group [20]. At the liberated N-terminus, coupling reactions were continued
and followed by Fmoc deprtections until the desired, full-length peptide sequence was made on
solid phase Scheme 1.3.

Scheme 1.2. HCTU activation of Fmoc-amino acids. Fmoc protected amino acid (1.5) reacts with
the HCTU coupling reagent (1.6) and the base, N-methylmorpholine (NMM), to form the activated
Fmoc-amino ester (1.7).
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Scheme 1.3. Fmoc-SPPS of the D-(KLAKLAK)2 peptide sequence.

Following peptide synthesis on solid phase, the cleavage and deprotection steps released
the peptide from the solid support and removed all side-chain protecting groups. The cleavage and
deprotection steps are effected by TFA (95%, 1-3 mL) with TES (2.5%, 25-75 L) and water
(2.5%, 25-75 L) scavenging reactive intermediates. The cleavage and deprotection cocktail was
concentrated under a stream of inert nitrogen. The crude peptide was then precipitated with cold
ether (5-10 mL), vortexed and centrifuged to remove the supernatant and the crude peptide was
isolated as a solid, white pellet, which washed twice more with cold ether. The crude peptide pellet
was dried in vacuo and then resuspended in a mixture of MeCN:H2O (1 mL, 50:50 v/v) with
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minimal addition of an ion-pairing reagent (0.1% TFA or FA) to enhance dissolution for LC/MS
analysis and purification.
1.3.3. ANALYSIS AND PURIFICATION OF D-(KLAKLAK)2 SEQUENCE BY LC/MS
Following peptide synthesis, peptide crude purity and identity was assessed by LC/MS. A
Waters C18 symmetry shield column, (5.5 M, 4.6 x150 mm) was used for the separation analysis.
Moreover, an eluent gradient composed of: 2-83% MeCN or MeOH in water with (0.1% TFA)
over 18 min was used for efficient peptide separation on the reverse phase column. Reaction
progress was followed at 220 nm for amide bond absorptions using a photodiode array (PDA)
detector. The crude peptide demonstrated a purity of 69% (Figure 1.6), while the purified peptide
produced an isolated purity of >90% (Figure 1.7). The observed crude impurities were primarily
due to failure sequences that accompanied incomplete coupling reactions of Fmoc-amino acids
Figure 1.6. Following purification by RP-HPLC, the isolated peptide was found to have a purity
of 93% in multiple eluent conditions composed of MeOH or MeCN in water and TFA (Figure
1.7). In order to confirm the identity of the purified, isolated peptide, ESI MS validated the
molecular weight of the D-(KLAKLAK)2 sequence, without detection of any significant impurities
(Figure 1.8). The pure peptide was freeze-dried and lyophilized to dryness, stored in the freezer
until further use.
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Figure 1.6. RP-HPLC chromatogram of the crude D-(KLAKLAK)2. Linear gradient 2-83%
MeOH (0.1% FA) over 18 min, with YMC Column-C18, (4.6 x 250 mm, 5.0 µm particle size) at
25 °C and flow rate of 1.0 mL/min with detection at 220 nm.
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Figure 1.7. RP-HPLC chromatogram of the purified D-(KLAKLAK)2. Linear gradient 2-83%
MeOH (0.1% FA) over 18 min, with YMC Column-C18, (4.6 x 250 mm, 5.0 µm particle size) at
25 °C and flow rate of 1.0 mL/min with detection at 220 nm.

Figure 1.8. ESI –MS spectra of the purified, isolated D-(KLAKLAK)2. MSD signal parameters:
Threshold: 150, Step size: 0.15, Mode: scan, Polarity: Positive, Mass range: 500 to 3000,
Fragmentation: 70, Gain: 1.0, Source: API-ES, Peak width: 0.10 min, Cycle time: 0.98 sec/cycle.
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1.3.4 CHARECTERIZATION OF THE D-(KLAKLAK)2 SEQUENCE BY CIRCULAR
DICHROISM SPECTROSCOPY
Circular Dichroism (CD) spectroscopy provides important structural information of
optically active chromophores over a wavelength range that is typically in the UV region (190-360
nm). CD spectroscopy aims to study chiral molecules of all types and sizes, but is used extensively
in the study of large biological molecules, including in the determination of peptide structures. In
relation to peptides, CD spectroscopy provides characteristic spectral traces that are consistent
with peptide secondary and some tertiary structure arrangements. For example, peptide random
coils or disordered structures exhibit a strong minimum band at 190 nm. Alternatively, ordered
peptide secondary structures such as the -helix (maximum at 190 nm, minima at 210, 230 nm),
the -sheets and turns (maximum at 200 nm, minimum at 220 nm) exhibit characteristic Cotton
effects that helps distinguish between different types of secondary structures (Figure 1.9). These
studies are also useful in determining structure, kinetics and thermodynamic stability of peptides
in a wide range of solvent, pH and temperature conditions.

Figure 1.9. CD spectra and secondary peptide structures. The CD spectrum of poly-L-lysine in αhelix, -sheet, and disordered (random coil) structures. 3D structural representation of
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corresponding peptide secondary structures and random coils. Figure adapted from Dr. Ramy S.
Farid- Discussion of CD Spectroscopy, a revised version of online lecture notes.

In this study, the structural properties of the isolated, pure D-(KLAKAK)2 sequence was
investigated on an Aviv Circular Dichroism (CD) Spectrophotometer (Model: 62A DS). The
peptide samples (30 – 220 M) dissolved in phosphate buffered saline (PBS), (8 g of NaCl, 0.2 g
of KCl, 1.44 g of Na2HPO4, 0.24 g of KH2PO4, adjusted the pH to 7.4 with HCl, dissolved in 1 L
of distilled H2O). The CD spectra of the D-(KLAKAK)2 sequence was collected from 190-260 nm
using 1 nm bandwidth and 0.5 min step size at with 30 spectra points at 25 oC. Triplicate
measurements were collected separately to ensure uniformity and reproducibility of the results.
Spectra were blank corrected, smoothed and data converted to molar ellipticity values from the
equation [θ] = θ /cl, where θ is the relative ellipticity (mdeg), c is the molar concentration of the
peptides (µM) and l is the path length of the cell (1 cm). The data was imported into Microsoft
Excel and the CD spectra plotted in terms of molar ellipticity vs. wavelength.
CD spectroscopy of D-(KLAKLAK)2 sequence revealed a peptide sequence that exhibits
α-helical character at lower (30 M) concentration ranges that are expected to be physiologically
relevant. At lower concentrations, the CD spectra suggests an -helical peptide structure according
to the minima observed at 210 and 230 nm with a strong maximum band apparent at 190 nm
(Figure 1.11). Many α-helical proteins are present in the inner membranes of bacterial cells or the
plasma membrane of eukaryotes, and sometimes in the outer membrane. They function as a major
structural component of transmembrane proteins that facilitates the passage of molecules and ions
in and out of the cell (i.e. transporter proteins). Interestingly, at higher concentrations (>100 M)
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the D-(KLAKLAK)2 sequence is seemingly transitioning to a -sheet or turn conformation with a
strong negative band detected at around 230 nm and a positive one at around 200 nm (Figure
1.10). These results suggests the D-(KLAKLAK)2 sequence contains a flexible secondary
structure, capable of transitioning between different conformations as a function of concentration.
This trend is anticipated to persist in different conditions, including variations in solvent, pH, ion
strength and temperatures.

Figure 1.10. CD Spectra of the D-(KLAKLAK)2 peptide sequence (30 – 120 M) in PBS buffer.
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1.4 BIOLOGICAL ACTIVITY OF D-(KLAKLAK)2 SEQUENCE IN BACTERIA AND
MAMMALIAN CELLS
Some antimicrobial peptides selectively inhibit and kill bacteria while maintaining low
mammalian cell cytotoxicity [27]. This selectivity can be attributed to the membrane differences
between bacteria and mammalian cell types. The exterior membranes of bacteria tend to be
predominantly negatively charged due to a composition of anionic phospholipids and glycolipids.
The mammalian cell exterior membranes are generally neutral in charge due to a mixed
composition of complex biologicals, including the neutrally charged sphingolipids and cholesterol.
Consequently, the positively charged D-(KLAKLAK)2 sequence was found to have higher binding
affinity and biological activity in bacteria vs. mammalian cell types.
Interestingly, the amphiphilic peptide sequence and -helical secondary structure were also
found to contribute to its cell translocation mechanism and localization onto the mitochondria. At
the localized organelle, the peptide sequence was found to disrupt the mitochondria membrane
integrity and biological function leading to its cytotoxic activity. Moreover, peptide translocation
was postulated to occur by membrane fusion and translocation into the cytosol via endosomal
transport and escape [14,15,28]. Alternatively, a receptor-mediated endocytic pathway was
reported with the incorporation of a targeting vector or homing domain specific for a cell surface
protein receptor (Figure 1.11) [29-33]. The latter is a crucial requirement for improving the
mammalian cell cytotoxic activity of the D-(KLAKLAK)2 sequence.
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Figure 1.11. Schematic description of cell permeability and cytotoxicity of the D-(KLAKLAK)2
sequence in bacteria and mammalian cell types.

1.5 DESIGN, SYNTHESIS, AND ANTI-CANCER ACTIVITY OF THE D-(KLAKLAK)2
BIOCONJUGATES.
In order to enhance the cytotoxic activity of the killer D-(KLAKLAK)2 sequence in
malignant mammalian cell types, such as in cancers, modifications to the primary sequence
composition and bioconjugation with small molecules, biologicals and cytotoxic drugs have been
incorporated [14,15,28]. For example, a new dual-targeting pro-apoptotic peptide (DTP) was
synthesized, characterized and evaluated for anti-cancer activity [29].
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Figure 1.12. Dual targeting pro-apoptotic peptide and mechanism of action for the amphiphilic
peptide: TPP-KFA-D-(KLAKLAK)2. Figure adapted from reference Chen, W.H. et. al. Sci. Rep.
2013, 3, 3468.

This peptide bioconjugate combined three components within its bioactive form. Namely,
the folic acid (FA) moiety for targeting the folate receptor (FR) overexpressed on the surface of
cancer cells that facilitates receptor-mediated endocytosis. The positively charged and
hydrophobic triphenylphosphine (TPP) moiety, facilitates cell permeability and mitochondria
localization for the cytotoxic activity of the D-(KLAKAK)2 sequence (Figure 1.12). This
bioconjugate was synthesized by Fmoc-SPPS, isolated and characterized by LC/MS followed by
its anti-cancer evaluation in KB, HeLa and COS7 cancer cells. Significantly, the bioconjugate was
found to be more active than the native, D-(KLAKAK)2 sequence, underscoring the importance of
homing and penetrating vectors for mammalian cancer cell cytotoxic activity.
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In a related example, the pH sensitive pHLIP peptide (GGEQNPIYWARY
ADWLFTTPLLLLDLALLVDADEGTCG) was linked via a reducible disulfide bond to the D(KLAKLAK)2 sequence [30]. The synthesis of the wild type (WT) pHLIP sequence was
accomplished by Fmoc-SPPS with the incorporation of a reactive cysteine residue at its C
terminus. Subsequently, the D-(KLAKLAK)2 sequence was also synthesized by Fmoc-SPPS with
a reactive cysteine at the N-terminus for coupling onto the pHLIP sequence by disulfide bond
formation. The pHLIP-S-S-D-(KLAKLAK)2 bioconjugate was purified via reversed-phase high
performance liquid chromatography (RP-HPLC). The purity of the peptides were determined by
RP-HPLC, and their identities were confirmed via matrix-assisted laser desorption ionization time
of flight mass spectrometry (MALDI-TOF-MS). Interestingly, the pHLIP peptide is a 36 residue
sequence derived from the C helix of bacteriorhodopsin, a transmembrane spanning protein, [31]
and shows the ability to insert across the lipid bilayer and form a transmembrane helix at lower
pHs found within the acidic tumor microenvironment [31]. Thus, the pHLIP sequence contains
tumor homing capabilities that would facilitate the delivery of cytotoxic agents directly within
tumors. This is because at a pH corresponding to the extracellular pH of tumors, the pHilip
sequence undergoes a pH-dependent conformational change driven by the protonation of aspartic
acid residues, promoting the insertion of its C-terminus across the cell membrane to form a
transmembrane α-helix [32]. In this manner, the (KLAKLAK)2 sequence internalized within the
cytosol of malignant tumor cells, such as, MDA-MB-231 breast cancer cell line and released by
disulfide bond reduction by the reducing tumor cytosol for anti-cancer activity (Figure 1.13).
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Figure 1.13. Schematic representation of the cell internalization and apoptosis activities of the
pHilip–(KLAKLAK)2 sequence. Figure adapted from Burns, K. E., McCleerey, T. P., Thevenin,
D. Sci. Rep., 2016, 6, 28465.

In a final example, the cytotoxic peptide D-(KLAKLAK)2 conjugated to amphiphilic poly
(β-thioester) copolymers were composed of ROS sensitive backbones and hydrophilic PEG side
chains [33]. The conjugates were prepared by Fmoc-SPPS, and functionalization of the peptide
onto the copolymer was accomplished by Michael addition of a reactive N-terminal Cys with the
acrylate-derived copolymer backbone. In solution, the peptide-functionalized copolymer selfassembled into micelle-type nanoparticles due to the hydrophobic interactions of the copolymer
backbone with the PEG and D-(KLAKLAK)2 moieties (Figure 1.14). The self-assembled
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polymer−peptide nanoparticles remarkably improved cellular internalization and accumulation of
the therapeutic D-(KLAKLAK)2 sequence in cancer cells. Compared to the free KLA peptide, the
anti-tumor activity of the peptide-copolymer conjugate was signiﬁcantly enhanced, up to ∼400
times, suggesting the eﬀectiveness in cancer treatment applications. The higher antitumor activity
of the nanoparticles was attributed to the eﬃcient disruption of mitochondrial membranes and
subsequent excessive ROS production in cells. The ROS production around the mitochondria
stimulated the swelling of nanoparticles and subsequent release of squaraine dyes. Squaraine
dyes are a class of organic dyes showing intense fluorescence, typically in the near infrared region.
They also form H-aggregates and signiﬁcantly contribute to photoacoustic (PA) signaling for
imaging the effects of ROS generation in live cells. In this manner, the self-assembled polymer
peptide nanotherapeutics may hold great promise in medicinal chemistry applications.

Fig.1.14. Self-assembled ROS-sensitive polymer-peptide conjugate (PPC) incorporating a reporter
for enhanced tumor treatment. Figure adapted from Qiao, Z. Y.; Zhao, W. J.; Cong, Y.; Zhang, D.;
Hu, Z.; Duan, Z. Y.; Wang, H. Biomacromolecules, 2016, 17, 1643–1652.
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1.6 NUCLEOLIPIDS: COMPOSITION, SYNTHESIS, CHARACTERIZATION AND
APPLICATIONS IN CANCER THERAPY
Nucleolipids are a special class of bioconjugates composed of a nucleoside and a lipophilic
moiety e.g. alkyl chain, cholesterol, vitamin or fatty acid. A representative example of a naturally
occurring nucleolipid consists of cytidinediphosphate diacylglycerol. This nucleolipid is
composed of cytidine diphosphate functionalized with a diacylglycerol moiety at the 5’diphosphate position. As such, the nucleolipid functions as a reactive intermediate for the
functional group-transfer of the phosphatidic acid group. The nucleolipid is formed by the reaction
of phosphatidic acid with cytidine-5-triphosphate resulting in the concomitant release of
pyrophosphate (Scheme 1.4). By the transfer of the phosphatidic acid group onto OH groups of
carbohydrates or proteins, glycolipids and lipoproteins are formed. Transfer to inosite or glycerol3-phosphate results in the formation of the membrane components phosphatidylinosite and
cardiolipin. Thus, the nucleolipid cytidinediphosphate diglycerol functions as a reactive
intermediate in the biosynthesis of phospholipids, such as phosphatidylinositol, and regulates
lipid-dependent signal transduction pathways [34]. Considering their relevance in biology,
chemical synthesis methods have been developed for generating new nucleolipids for potential
therapeutic applications.

Scheme 1.4. Biosynthesis of Cytidinediphosphate diglycerol. Figure adapted from Liu, X.; Yin, Y.; Liu, Z. Nature, 2014, 5,
4244.

27

1.6.1 AMINO ACYLNUCLEOLIPID
The aminoacyl nucleolipids are an interesting class of synthetic amphiphilic nucleolipid
bioconjugates. A variety of synthetic aminoacyl nucleolipids (Figure 1.15) have been prepared
and found to self-assemble into higher-ordered biomaterials for applications in gene therapy,
medicinal chemistry and biotechnology. These interesting properties stem from the amphiphilic
nature of the bioconjugate, which readily self-assembles into high-order nanoparticle formulations
or aggregates, which imparts its biological activity. For example, the synthetic guanosine
aminoacyl nucleolipids (1.16, 1.17) displayed the ability to form stable G-tetraplexes (G-tetrads)
in organic solvents [35], and were also found to behave as Li+ and K+ ion chelators. These materials
were also found to facilitate transport of H+/OH ions in the presence of an applied pH gradient
[36]. Moreover, aminoacyl nucleolipids, 1.16 and 1.17 showed moderate to weak activity (IC50:
17 - >103 µM) in an anti-proliferative assay across a panel of five tumor cell lines underscoring
their potential in biomedical applications [36]. In a related case study, a cationic aminoacyl
surfactant (1.18) demonstrated micelle forming capabilities in water according to DLS studies and
modest cell toxicities (IC50: 19 – 98 µM) relative to the cytotoxic cetyl triethylammonium bromide
(CTAB) cationic amphiphile in a panel of human, rat and murine cell lines [37]. In light of their
abilities to form stable cationic assemblies, the aminoacyl nucleolipids have been applied to gene
delivery and treatment applications in-vitro [38]. The development of short interfering RNAs
(siRNAs) have enabled the application of site-specific mRNA knockdown through the RNA
interference (RNAi) pathway [34]. In spite of its potential in gene therapy applications, siRNAs
remain limited by poor cell permeability. In an effort to overcome this limitation, siRNA delivery
agents (transfection agents) have been developed to effectively condense and deliver siRNA across
the amphiphilic cell membrane for RNAi activity.
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Figure 1.15. Structures of synthetic aminoacyl nucleolipids.

In this scope, a small library of synthetic polycationic nucleolipids have been formulated
for siRNA transfection within HeLa cells for potent Vascular Endothelial Growth Factor (VEGF)
knockdown [38]. The spermine derived aminoacyl nucleolipid (1.19) exhibited comparable siRNA
transfection efficiencies (>90% VEGF knockdown) and cell death (~20%) as the benchmark
Lipofectamine-based siRNA transfections, underscoring the utility of nucleolipids as siRNA
transfection vectors. Moreover, metabolically stable variants of aminoacyl nucleolipids (Figure
1.15) have also been formulated for siRNA delivery applications in HeLa cells [39]. This cationic
nucleolipid formed stable ionic complexes with anti-VEGF siRNA leading to potent VEGF
knockdown (>90%) in HeLa cells [39]. These examples effectively demonstrate the fruitful
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implementation of aminoacyl nucleolipids in condensing oligonucleotides and transporting them
within cells for medicinal chemistry applications.

In our contribution, an aminoacyl nucleolipid was based on a guanine nucleoside, which
contains the ability to participate in H-bonding interactions, an aminoacyl group for potential ionic
bonding, and lipids which enable the self-assembly through non-polar interactions (Figure 1.16)
[40]. The aminoacyl nucleolipid designed and synthesized in our study was anticipated to interact
favorably with the promoter sequence of the GRP78 oncogene. This proposed DNA binding ligand
was expected to unleash potent anti-cancer effects in GRP78 overexpressing tumors.

Figure 1.16. Chemical structure and DNA-binding interactions of an aminoacyl nucleolipid.
Figure adapted from Patel, P.; Hanawa, E.; Yadav, R.; Samuni, U.; Marzabadi, C.; Sabatino, D.
Bioorg. Med. Chem. Lett. 2013, 23, 5086-5090.

Our study began with the solution phase synthesis of an aminoacyl nucleolipid building
block, 1.28. The synthetic strategy involved the production of N-isobutyryl 5’-carboxy 2’,3’-bisO-(carbobenzyloxy) guanosine, 1.24, (Scheme 1.5). N-isobutyrroyl 5’-dimethoxytrityl guanosine,
1.21, was used to attach the Cbz protecting groups with benzylchloroformate and DMAP in DCM.
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Following carbomylation, 1.22, was detritylated using 3% trichloroacetic acid in DCM (3%
TCA:DCM) affording the guanosie analog, 1.23, in 98% yield. N-isobutyrryol-2’,3’-bis-O(carbobenzyloxy)guanosine, 1.23, was then oxidized to the carboxylic acid, 1.24, in 82% yield,
using TEMPO oxidation.

Scheme 1.5. Synthesis of N-isobutyryl 5’-carboxy 2’,3’-bis-O-(carbobenzyloxy) guanosine, 1.24.
Conditions: (a) DMAP, benzyl chloroformate, DCM, 0o C then r.t., 72 h, 77%, (b) 3%TCA:DCM,
r.t., 15 min, 98%, (c) TEMPO, BAIB, MeCN:H2O (50:50 v/v), r.t., 15 h, 82%.

Fmoc-Lys(Boc) was coupled at the 5’-carboxy position of 1.24 using N-ethoxycarbonyl
1,2-ethoxy-1,2-dihydroquinoline,

EEDQ,

(2

equiv)

as

coupling

reagent

and

N,N-

diisopropylethylamine, DIEA (2 equiv) as the base in DMF. The reaction produced the desired
product in >99% yields. The Cbz protecting groups were deprotected using hydrogenolysis,
generating diol 1.26 in quantitative yields (Scheme 1.6). The product was acylated with an excess
of palmitoyl chloride to afford the protected aminoacyl nucleolipid 1.27 in >99% yield. The Bocprotecting group of 1.27 was removed using 50% TFA:DCM, followed by salt exchange to the
hydrochloride salt with aqueous HCl. The desired aminoacyl nucleolipid, 1.28, was obtained in
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quantitative yields in this final reaction step and its purity and composition was ascertained by 1H
NMR, 13C NMR, IR, UV/Vis, and MS techniques. A variety of experimental techniques, including
gel shift mobility assays, thermal denaturation and CD spectroscopy were used to confirm the
binding interactions of the aminoacyl nucleolipid with the GRP78 DNA.

Scheme 1.6. Solution phase synthesis of aminoacyl nucleolipid. Conditions: (a) H2, 10% Pd/C,
EtOH, r.t., 1.5 h, >99% (b) palmitoyl chloride, DMAP, pyr., 2 h, >99% (c) 50% TFA:DCM, 2 h,
r.t., then 1 M HCl, 3 h, >99%.

In order to assess the anti-cancer activity of the aminoacyl nucleolipid, a cancer cell linescreening assay was conducted against a panel of 60 cell lines at the National Cancer Institute
(NCI). A single dose (10 µM) test was performed with the synthetic aminoacyl nucleolipid and
cell viability was determined following 48 h incubation with cancer cells. A sulforhodamine B
(SRB) cell viability assay was performed to determine cell death activity. The aminoacyl
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nucleolipid was found to exhibit potent (90%) and selective anti-cancer activity against a SR
human lymphoblastic leukemia cancer cell line (Figure 1.17). Interestingly, GRP78 is
overexpressed in leukemic blasts of adult patients and in early relapse childhood leukemia
suggesting a correlation between the GRP78 DNA binding affinity and the anti-leukemic activity
of the aminoacyl nucleolipid. We are currently investigating the molecular basis for the potent and
selective anti-cancer activity of the aminoacyl nucleolipid.

Figure 1.17. Cell death of human leukemia cell lines following treatment with
aminoacylnucleolipid, 1.28, (10 µM) for 48 h.

1.7. THESIS RESEARCH OBJECTIVES
In an effort to exploit the cell death effects of D-(KLAKLAK)2, and improve its ‘drug-like’
properties, chemically robust and structurally pre-organized amphiphilic nucleolipids are proposed
to enhance cell permeability and mitochondria localization in tumor cell types for potent and longlasting anti-cancer effects (Figure 1.18). These amphiphilic nucleolipids are inspired from our
previous study on the so-called aminoacyl nucleolipid [40]. Building upon this work, the novel
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nucleolipids described in this thesis are rationally designed to contain a reactive 5’-carboxy group
for introduction within the pro-apoptotic D-(KLAKLAK)2 sequence by solid phase peptide
synthesis. The nucleolipid is based on a thymidine nucleoside that provides a chemically resilient
and structurally pre-organized scaffold, and long chain alkylamines that are proposed to facilitate
cell penetration and mitochondria localization within tumor cell.

Figure 1.18. Design and structure of the amphiphilic nucleolipids synthesized in this study.

In this study, the design, synthesis, characterization, and cancer cell death activity of a new
class of peptide nucleolipids is described. This thesis will present a new class of palmitamide and
nucleolipid derived D-(KLAKLAK)2 bioconjugates in Chapter 2. A presentation of its synthesis,
biophysical and anti-cancer activity is described and related to the native, peptide sequence.
Chapter 3 will describe a diversity oriented synthesis approach for making chemically diverse
nucleolipids that may be useful in exploring structure-function relationships of the bioconjugates
and their cancer cell targets. This chapter will also highlight the potential of this methodology; in
building libraries from libraries of nucleolipid derivatives that may be easily incorporated within
other lead biologicals or in themselves present an element of anti-cancer activity. Finally, the D(KLAKAK)2-nucleolipid conjugates may also be functionalized with tumor homing vectors, for
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selective and effective treatment of cancer cell types. The latter forms an important part of the
precision medicine initiative currently in progress in our group for the rapid and selective diagnosis
and treatment of cancer. These contributions to knowledge (Chapter 4) and supporting information
(Appendix) will be presented as the final sections of this thesis.
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CHAPTER 2. SYNTHESIS, CHARACTERIZATION AND ANTI-CANCER ACTIVITY
OF A PEPTIDE-NUCLEOLIPID BIOCONJUGATE
2.1 ABSTRACT
The nucleolipids form an interesting class of bioconjugates displaying desirable biophysical and biological properties for applications in cancer detection and therapy. They own the
ability to self-assemble into amphiphilic higher-order nanostructures which contributes to their
biological relevance in medicinal chemistry. Therefore, nucleolipids have also been used in the
delivery of hydrophobic drugs, biologicals and fluorescent probes for the detection and treatment
of malignant cells. Structurally, the amphiphilic nucleolipids are composed of hydrophobic lipid
appendages that are connected to a nucleoside core forming an amphiphile that may be further
functionalized for medicinal chemistry applications. In spite of their utility, the nucleolipids
remain limited by tedious total synthesis strategies, solubility issues in biological media and the
susceptibility towards aggregation that may limit their biological function in live cells. In order to
address these limitations, this chapter describes the synthesis, characterization and anti-cancer
activity of a new class of amphiphilic peptide-nucleolipid bioconjugate. The approach began with
the synthesis of a reactive carboxy-derived thymidine nucleolipid. The nucleolipid is based on a
thymidine nucleoside that provides a chemically resilient and structurally pre-organized scaffold,
and long chain alkylamines that are proposed to facilitate cell penetration and mitochondria
localization for anti-cancer activity within tumor cells. Key to the synthesis strategy is a reductive
amination procedure for installing the alkylamines onto the 3’-aldehyde derived thymidine
building block. In this manner, a diversity oriented approach may be envisioned for the generation
of functionally diverse nucleolipids. Deprotection and oxidation afforded the 5’-carboxy-derived
nucleolipid which was then conjugated to the D-(KALAKLAK)2-AK sequence. This peptide
sequence is known as the killer peptide due to its ability to disrupt mitochondria structure and
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function ultimately leading to apoptosis. The nucleolipid is anticipated to function as a vector,
facilitating the penetration of the D-(KALAKLAK)2-AK in tumors for potent anti-cancer activity.
This chapter will further describe the outcome of a first representative example of a peptidenucleolipid bioconjugate.
2.2 CHAPTER OBJECTIVES
This thesis chapter aims to describe the design, synthesis and characterization of a new
class of peptide nucleolipid bioconjugates for anti-cancer applications. In order to accomplish
these research objectives, a simple, reliable and reproducible synthesis strategy for making a 5’carboxy 3’-hexadecylamine thymidine nucleolipid has been developed. This synthesis strategy
features a key reductive amination step that was used to install hexadecylamine onto the 3’aldehyde derived thymidine. This reaction afforded the desired nucleolipid in good yields and
purities. Additionally, it may also be extended to other alkylamines for making libraries of
functionally diverse nucleolipids for exploring structure-activity relationships with malignant
cellular targets. Following deprotection and oxidation of the 5’-OH to the 5’-CO2H, the carboxyderived nucleolipid was characterized by a combination of chromatography and spectroscopy to
ascertain identity and purity. The second objective is related to the solid phase peptide synthesis
of the antimicrobial peptide D-(KLAKLAK)2. In spite of its antiseptic activity, the D(KLAKLAK)2 sequence lacks mammalian cell permeability and cytotoxicity. Many efforts have
been developed to improve the cytotoxic activity of the D-(KLAKLAK)2 sequence in malignant
mammalian cell types. Among the most commonly used methods is conjugation of the peptide
with amphiphilic vectors that improve permeability across the mammalian cell membrane and
promote localization at the mitochondria for cytotoxic activity. In the second objective, a solid
phase synthesis approach has been developed for making an orthogonally protected D40

(KLAKLAK)2-AK sequence. Liberation of the C-terminus amino group from the Lys side chain
facilitated the development of a HCTU-based coupling reaction in between the peptide and
carboxy derived nucleolipid to generate the peptide-nucleolipid bioconjugate. The desired peptide
nucleolipid bioconjugate was then characterized by a combination of chromatography,
spectroscopy and microscopy to fulfill the requirement of our third research objective, related to
the characterization of the peptide-nucleolipid bioconjugate. In collaboration with Suing Huang
(Ph.D. student) in the laboratory of Dr. Uri Samuni (Department of Chemistry, Queen’s College)
dynamic light scattering (DLS) and transmission electron microscopy (TEM) experiments were
accomplished in order to validate the higher-order nanoparticle formulation of the bioconjugate.
The final research objective in this study was aimed towards investigating the potential anti-cancer
activity of the peptide nucleolipid bioconjugate. A screening assay was performed at the National
Cancer Institute (NCI), in which a single dose treatment of the peptide nucleolipid bioconjugate
was administered to 60 different cancer cell lines to determine inhibitory growth effects and
cytotoxicity. Completion of these research objectives led to the identification of a lead peptide
nucleolipid bioconjugate that may have anti-cancer utility in a selected panel of cancer cells lines.
This thesis chapter will provide additional insights to the completion of the research objectives
towards the synthesis, characterization and anti-cancer evaluation of a newly developed peptidenucleolipid bioconjugate.
2.3 INTRODUCTION
The so-called “killer” peptide sequence D-(KLAKLAK) 2 has been originally designed and
developed as an antimicrobial agent [1]. This peptide sequence was found to maintain selective
cytotoxic activity towards bacteria, but not in mammalian cell types. The chemical basis for its
selectivity has been attributed to its poly(cationic) amphiphilic nature, which facilitates
41

translocation across the negatively charged bacterial cell membrane, but with limited permeability
across the zwitterionic membrane of mammalian cell types [2]. Once internalized within cells, the
positively charged D-(KLAKLAK)2 sequence has been found to associate to the surface of the
mitochondria causing dissipation of the negatively charged mitochondrial membrane potential [3].
This depolarization resulted in a loss of mitochondrial structure integrity that caused membrane
rupture and the release of mitochondrial contents into the cytoplasm. The release of the cell death
effectors from the mitochondria, including cytochrome c, the second mitochondrial-derived
activator of caspase (Smac/DIABLO) and the apoptosis-inducing factor (AIF) ultimately resulted
in programmed cell death [4]. In an effort to exploit the cell death effects of D-(KLAKLAK)2,
modifications to the primary sequence [5] and conjugation with cell penetrating, targeting peptides
and proteins [6-14] have resulted in improved cell translocation and cytotoxic activity within
malignant mammalian cell types, such as in human cancers. In spite of their utility, effective
methods for the safe and long-lasting administration of peptide-based therapeutics are still in
widespread demand. Limitations which include poor peptide cell permeability, minimal exposure
and resident time at the target tumor site for activity have impeded the translation of bio-active
peptides such as the D-(KLAKLAK)2 sequence from pre-clinical to clinical use. In an effort to
mitigate these limitations and improve the ‘drug-like’ properties of the pro-apoptotic D(KLAKLAK)2 sequence, an amphiphilic nucleolipid is proposed to enhance cell permeability and
mitochondria localization in tumors, resulting in potent and long-lasting anti-cancer effects.
The nucleolipids represent an interesting class of bioconjugates with the ability to form
stable, higher-ordered nanostructure formulations for potential applications in medicinal chemistry
[15, 16]. For example, they have been shown to form complexes with short-interfering RNA
(siRNA), facilitating siRNA transfection across cell membranes and leading to the down-
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regulation of mRNA expression in cancer cells [17-19]. Moreover, the synthesis, GRP78 oncogene
binding and selective anti-cancer activity of a novel aminoacyl nucleolipid bioconjugate within
the SR human leukemia cancer cell line has been described [20]. Thus, the nucleolipids have
effectively served as robust delivery vehicles for biologicals and as potent cytotoxic agents for
enhancing the cell death responses in cancer. In this study, a thymidine-derived nucleolipid is
rationally designed to contain a reactive carboxy group for coupling with the pro-apoptotic D(KLAKLAK)2 sequence. This strategy will enable the introduction of functionally diverse
nucleolipids within the D-(KLAKLAK)2 sequence in order to improve structure-activity
relationships in malignant cancer cell types.
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2.3.1 SYNTHESIS, CHARACTERIZATION AND ANTI-CANCER ACTIVITY OF A
PEPTIDE NUCLEOLIPID BIOCONJUGATE
Niki Ranaa, Suiying Huangb, Pradeepkumar Patela, Uri Samunib, and David Sabatinoa,*
a

Department of Chemistry and Biochemistry, Seton Hall University, 400 South Orange Avenue, South Orange, New
Jersey 07079, United States
b
Department of Chemistry, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing , New York
11367, United States and the Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City
University of New York, New York, NY 10016

Figure 2.1. Graphical abstract of the peptide-nucleolipid bioconjugate developed in this study.
Figure adapted from Rana, N., Huang, S.; Patel, P.; Samuni, U.; Sabatino, D. Bioorg. Med.
Chem. Lett., 2016, 26, 3567–3571.

2.3.2. RESULTS AND DISCUSSION
2.3.3. SYNTHESIS OF A 5’-CARBOXY 3’-HEXADECYLAMINE THYMIDINE
DERIVED NUCLEOLIPID
The synthesis of nucleolipid 2.6 (Scheme 2.1) was initiated by the regioselective
attachment of the allyl group at the 3’-hydroxyl of commercially available 5’-O-(4-
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dimethoxytrityl) DMT- thymidine, 2.1. The allylation reaction proceeded smoothly with sodium
hydride (NaH) as base, and allyl bromide as alkylating reagent resulting in 87% yield of the monoallylated nucleoside, 2.2, and without any observable allylation on thymine. The allyl group in 2.2
was then oxidized to the aldehyde, 2.3, and isolated in 84% yields following silica gel column
chromatography. The reactive 3’-aldehyde was subsequently condensed with hexadecylamine and
reduced using sodium cyanoborohydride to yield the alkylamine–derived thymidine, 2.4. This twostep one-pot reductive amination reaction favored the formation of the desired intermediate, 2.4,
in 43% yields. In this reaction, the conversion of the imine to secondary amine was closely
monitored by 1H NMR which confirmed the disappearance of the iminium proton (δ: 6.85 ppm)
upon complete reduction of the Schiff base. Following quantitative removal of the 5’-DMT group
using trichloroacetic acid (TCA), a TEMPO-mediated oxidation reaction converted the 5’-hydroxy
to the carboxylic acid, 2.6, in 50% yield. Each reaction intermediate and the final product, 2.6,
were characterized by NMR, IR spectroscopy and by MS to confirm purities and identities.
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Scheme 2.1. Synthesis of 5’-carboxy-derived thymidine nucleolipid, 2.6
Conditions: (a) allyl bromide, NaH, THF, sonication, r.t., 3hr, 87%, (b) 4% OsO4 in t-BuOH,
NMO, Na2S2O4, NaIO4, acetone:phosphate buffer (3:1 v/v), 84%, (c) i) 1-hexadecylamine, THF,
r.t., 20 min, ii) NaBH3CN, THF, r.t., 4hr, 43% (d) 3% TCA:DCM, r.t., 4h, >99%, (e) i) TEMPO,
BAIB, DCM, r.t., 2h, ii) MeCN:Water r.t., 24 hr, 50%.

2.3.4 DESIGN AND SYNTHEIS OF D-(KLAKLAK)2-AK PEPTIDE SEQUENCE AND ITS
RELATED ANALOGUES.
The thymidine derived nucleolipid was rationally designed and synthesized to contain a
reactive carboxy group for coupling with the pro-apoptotic D-(KLAKLAK)2 sequence, to afford
the desired peptide-nucleolipid bioconjugate (Figure 2.1). The thymidine nucleoside provides a
chemically resilient and structurally pre-organized scaffold [21] while the long chain alkylamine
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is anticipated to enhance cell permeability and mitochondria localization of the D-(KLAKLAK)2AK sequence for potent anti-cancer activity. Moreover, the native peptide, D-(KLAKLAK)2-AK,
and the palmitamide-derived D-(KLAKLAK)2-AK sequences were also synthesized and used as
controls to evaluate the influence of the nucleolipid on the biophysical, structural and biological
properties of the D-(KLAKLAK)2-AK sequence (Figure 2.2A).

Figure 2.2 A. Peptide structures. The D-(KLAKLAK)2-AK peptide scaffold with R1(red) = H or
FITC, R2(blue) = H, Nucleolipid or Palmitamide. R1, R2 = H, 2, R1 = FITC, R2 = H, 5, R1 = H, R2
= Palmitamide, 3, R1 = H, R2 = Nucleolipid, 4, R1 = FITC, R2 = Palmitamide, 6, R1 = FITC, R2 =
Nucleolipid, 7. All amino acids are in their D-configuration.

The synthesis of the D-(KLAKLAK)2-AK sequence, 2.7, was accomplished by
conventional Fmoc-solid phase peptide synthesis on a Rink amide hydrophilic poly(ethylene
glycol) resin (Nova PEG, 0.47 mmol/g) [22]. At the N-terminus of the peptide sequence an
aminohexanoic acid (AHx) linker was attached for the incorporation of fluorescein isothiocyanante
(FITC) [23]. Following cleavage and deprotection, the FITC-labeled peptide sequence, 2.10, was
47

isolated by RP-HPLC for characterization studies. At the C-terminus, an orthogonally protected
Lys(Dde) residue was selectively deprotected on solid-phase using hydroxylamine hydrochloride
buffered with imidazole. These mild conditions have been shown to cleave the Dde group without
concomitant Fmoc-deprotection that has been shown to occur when hydrazine is used as Dde
deblocking reagent [24]. Bioconjugation was first attempted by coupling palmitic acid at the Cterminus of the partially deprotected peptide sequence, 2.14, bound to the solid support (Scheme
2.2). Optimized conditions for peptide coupling reactions using HCTU as coupling reagent and
NMM as base were adopted for making the desired bioconjugates on solid support.
The palmitamide-derived D-(KLAKLAK)2-AK sequence was Fmoc-deprotected and
either coupled with FITC at the N-terminus, followed by cleavage and deprotection from solidphase, or was directly cleaved and deprotected for LCMS analysis and purification. The
palmitamide-derived D-(KLAKLAK)2-AK sequence, 2.9, and the FITC-labeled sequence, 2.12,

Scheme 2.2. Synthesis of FITC and non-FITC labeled D-(KLAKLAK)2-AK conjugated with
nucleolipid 2.6 or with palmitic acid.
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were isolated by RP-HPLC and their identities were confirmed by MS. These coupling conditions
were adopted for the synthesis of the nucleolipid-derived D-(KLAKLAK)2-AK sequence, which
was also produced respectively 2.8 and 2.11, without and with the FITC label. In either cases, the
peptide bioconjugates were isolated in sufficient yields (10-33%) and purities (≥96%) for the
structure-activity relationship studies.

2.4 CHARACTERIZATION OF D-(KLAKLAK)2-AK AND ITS RELATED
ANALOGUES.
The peptide bioconjugates were anticipated to display greater hydrophobicity relative to
the native D-(KLAKLAK)2-AK sequence. The enhanced hydrophobic character of cellpenetrating peptides has been shown to improve their membrane translocation, presumably due to
the favorable non-polar interactions in between the hydrophobic side-chain residues of the peptides
and the long-chain alkyl groups found within the lipid bilayer [25]. Comparison of the retention
times on RP-HPLC (Figure 2.2. B) for the native, D-(KLAKLAK)2-AK sequence, 2.7, RT = 6.5
min, with the palmitamide-derived D-(KLAKLAK)2-AK, 2.9, RT = 17.6 min, and the nucleolipidderived D-(KLAKLAK)2-AK, 2.8, RT = 11.3 min, confirmed that the palmitamide, followed by
the nucleolipid produced the greatest hydrophobic effects onto the native D-(KLAKLAK)2-AK
sequence.
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Figure 2.2 B. RP-HPLC comparison study of the native, nucleolipid and palmitamide-derived D(KLAKLAK)2-AK biooconjugates. Column: Waters Symmetry Shield C18, 5µm, 4.6x150 mm
Mobile Phase: 2-80% MeCN:H2O_0.1%FA PDA detection at: 220 nm.

The complete LC/MS characterization data for the peptides synthesized in this study is
provided in Table 2.1. Of note, pure peptides were isolated following RP HPLC purification in
purities>95%. Peptide purities were also confirmed in two different eluent systems which indicated
single isolated peptide peaks at their characteristic retention times. The molecular weight identities
of the peptides were confirmed as their mass:charge, in which multiple charge states, presumably
due to the positively charged Lys ammonium groups were detected on ESI MS. Nonetheless, the
peptides were isolated and characterized by LC/MS in sufficient quantities and purities for
investigating their biophysical, structural and biological properties.
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Table 2.1 Characterization data of peptides
b

h
Isolated
Yield(%/mg)

i
M.W.
(g/mol)
Expt(Theoratical)

56/(21.4)

508.5(507.0)

3

f

7.5

c

d

>99

64/(29)

459.7(459.0)

4

f

6.5

d

e

>99

33/(8.3)

518.5(519.3)

4

g

f

96

10/(2.1)

468.8(468.4)

5

f

11.3

d

>99

20/(4.0)

445.8(445.0)

5

f

10.5

d

5/(2.0)

493.6(492.6)

5

g

15.4

30/(4.8)

546.9(546.2)

5

g

10.5

Sequence

1

D-(KLAKLAKKLAKLAK)

93

c

2

AHx-D(KLAKLAKKLAKLAK)-AK

68

3

AHx-D(KLAKLAKKLAKLAK)-AKC H O (Palmitamide)
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4

AHx-D(KLAKLAKKLAKLAK)-AKC28H48N3O5 (Nucleolipid)

42

5

FITC-AHx-D(KLAKLAKKLAKLAK)-AK

93

f

6

FITC-AHx-D(KLAKLAKKLAKLAK)-AKC16H31O (Palmitamide)

93

g

7

FITC-AHx-D(KLAKLAKKLAKLAK)-AKC28H48N3O5 (Nucleolipid)

82

16

a

a

Entry

Crude
Purity
(%)

Isolated
Purity (%)
>99

j

Z

k
RT
(min)

17.6

l
RT
(min)

6.9

4.2

e

13.8

31

>99

g

96

6.3

6.0

e

e

5.7

10.5

Crude purities by RP-HPLC at 220 nm. bIsolated purities by RP-HPLC at 220 nm using c2-83%

MeCN/H2O with 0.1% TFA over 18 min, d2-80% MeCN/ H2O with 0.1% FA over 17 min, e20-80
MeCN/ H2O with 0.1% FA over 17 min, f2-80% MeOH/ H2O with 0.1% FA over 17 min, g20-80
MeOH/H2O with 0.1% FA over 17 min. hIsolated yields based on the resin loading. iObserved
mass (expected mass) as [M+H]+/Z as detected by LCMS. jCharged state of the peptides as
detected by LCMS in positive mode. kRetention times using methanol/water. lRetention times
using acetonitrile/water. ( c2-83% MeCN/H2O with 0.1% TFA over 18 min, d2-80% MeCN/ H2O
with 0.1% FA over 17 min, e20-80 MeCN/ H2O with 0.1% FA over 17 min, f2-80% MeOH/ H2O
with 0.1% FA over 17 min, g20-80 MeOH/H2O with 0.1% FA over 17 min.)
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The hydrophobicity of the peptide bioconjugates was also confirmed by the DLS zeta
potential measurements and the logP values evaluating the octanol:water partition coefficients of
the FITC-labeled peptides at 490 nm (Table 2.2). Furthermore, UV-Vis spectroscopy also
confirmed the characteristic absorption bands of the peptide bonds (λmax ~ 220 nm) and the thymine
base (λmax ~ 260 nm) corresponding to the nucleolipid-derived D-(KLAKLAK)2-AK, 2.8, (Figure
2.2C).

Figure 2.2C. UV/Vis spectroscopy (190–300 nm) of the peptides. Inset shows the nucleolipidderived D-(KLAKLAK)2-AK, absorbance at 260 nm.

CD spectroscopy was then used to evaluate the secondary structures (if any) of the peptides
in H2O:TFE. The combination of H2O:TFE has been especially useful in mimicking the
amphiphilic lipid bilayer microenvironment that has served to stabilize peptide secondary
structures in solution [26]. In this study, the native, D-(KLAKLAK)2-AK sequence, 2.7, displayed
a stable, α-helical secondary structure (65% helicity), while the palmitamide-derived D(KLAKLAK)2-AK, 2.9, displayed enhanced helicity (76%) and the nucleolipid-derived D52

(KLAKLAK)2-AK 2.8, demonstrated a less stable (42%) α-helical secondary structure (Figure
2.2D and Table 2.2).

Molar Ellipticity (*10E+05)

2.00
1.00
Wavelength (nm)

0.00
190

210

230

250

-1.00
-2.00
-3.00
D-(KLAKLAK)2-AK-Nucleolipid
-4.00

D-(KLAKLAK)2-AK-Native
D-(KLAKLAK)2-AK-Palmitic acid

Figure 2.2D. CD spectra of peptides at 12.5 µM in H2O: TFE (50:50, v/v)

Many amphiphilic cell-penetrating peptides adopt α-helical secondary structures. In certain
cases, this peptide motif functions as a recognition site with other membrane spanning proteins
(such as the pore proteins) and facilitates cellular translocation activity [27]. The amphiphilic αhelical peptides, 2.7, 2.9 and 2.8, were subsequently analyzed by DLS and TEM to determine ionic
charge, size, shape and particle distributions (Figure 2.3). The DLS data (Table 2.2 confirmed
positively charged peptide ionic structures according to the zeta-potential measurements obtained
in H2O. The size distributions (60 – 300 nm) detected by DLS and TEM were found to be
comparable and indicated a single, major population of nanoparticles for each formulation (Figure
2.3).
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Table 2.2. Structural and biophysical properties of the peptide sequences.
Sequencea

AHx-D-(KLAKLAK)2-AK
AHx-D-(KLAKLAK)2-AK-R1
AHx-D-(KLAKLAK)2-AK-R2
FITC-AHx-D-(KLAKLAK2-AK
FITC-AHx-D-(KLAKLAK)2 AK-R1
FITC-AHx-D-(KLAKLAK)2)-R2

%
Helicityb

65
76
42
n.a.
n.a.
n.a.

Hydrophobicityd

#of
Helical
residuesc

%AcN
elution
17
32
25
24
22
42

9
11
6
n.a.
n.a.
n.a.

Size(nm)

cLogP

DLS e

TEM f

n.a.
n.a.
n.a.
-1.44±0.40
-0.36±0.02
-0.41±0.05

270±80
190±70
310±90
n.a.
n.a.
n.a.

70-150
70-150
60-120
n.a.
n.a.
n.a.

Zeta
potential
g
(mV)

30
7
6
n.a.
n.a.
n.a.

Structure and comparison of hydrophobicity and helicity of the D-(KLAKLAK)2-AK analogues.
a

Sequence compositions D-(KLAKLAK)2-AK with R1 = palmitamide, R2 = nucleolipid, and FITC,

b

% Helicity calculated from observed ellipticity [Ɵ] at 222 nm using CD spectroscopy, c# of helical

residues calculated from the % helicity determined using CD spectroscopy, dHydrophobicity
measured as % acetonitrile elution from the RP-HPLC C18 column, LogP values (average and
standard deviation of three independently conducted experiments) calculated from partitioning
between 1-octanol and 10mM Tris pH 7.4 measured for the FITC-labeled (KLAKLAK)2 peptides
using UV-Vis spectroscopy at 492 nm,

e,f

Reported size of the peptide-based nanoparticle

formulations based on DLS and TEM measurements. gZeta potential measurements for the peptide
samples obtained in water at 25ºC.

For example, the native D-(KLAKLAK)2-AK sequence, 2.7, displayed, uniform, square
shaped particles ranging in sizes from 70 – 270 nm. The palmitamide-peptide bioconjugate, 2.9,
produced smaller, spherical-shaped particle sizes (70 – 190 nm), while the nucleolipid-peptide
bioconjugate 2.8, demonstrated the largest particle size formulation (60 – 310 nm). Taken
altogether, these results suggests that the peptides may exhibit favorable biophysical and structural
properties for their applications in molecular cancer cell biology. Considering the self-assembly
54

and nanoparticle formulation of similar amphiphilic D-(KLAKLAK)2 sequences have led to
significant anti-cancer effects [28] the cancer cell line toxicities of the peptides were subsequently
evaluated.

Figure 2.3. TEM images and DLS particle diameter size distributions of A) The native D(KLAKLAK)2-AK sequence, 2.7, B) the palmitamide-derived D-(KLAKLAK)2-AK sequence,
2.9, and C) the nucleolipid-derived D-(KLAKLAK)2-AK sequence, 2.8.

2.5 BIOLOGICAL EVALUATION OF THE D-(KLAKLAK)2-AK SEQUENCE AND ITS
RELATED ANALOGUES
A lethality assay was performed against a panel of 60 cancer cell lines at National Cancer
Institute (NCI) [29]. A single dose screen was performed with the native, D-(KLAKLAK)2-AK
sequence, 2.7, (10 M), the palmitamide-derived D-(KLAKLAK)2-AK sequence, 2.9, (7.25 M),
and the nucleolipid-derived D-(KLAKLAK)2-AK sequence, 2.8, (2.13 M). The cell growth data
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(Figures 2.4-2.6) indicated that the peptides were found to be most active towards a panel of nonsmall cell lung carcinoma (NSCLC). Interestingly, the palmitamide and nucleolipid-derived D(KLAKLAK)2-AK sequences, 2.9 and 2.8, showed the highest toxicity (~30%) within the A549
NSCLC cell line, resulting in a 1.5-fold enhancement relative to the native D-(KLAKLAK)2-AK
sequence, 2.7, (~20%) (Table 2.3).

Table 2.3. NCI-60 cancer cell line screen lethality (% cell death) data for a selection of human
Non-Small Cell Lung Cancer cell lines.
Lethality (% cell death) in NSCLC
Sequence
A549
NCI-H226
NCI-H522
Native, 2.7
19
1
14
Palmitamide, 2.9
32
0
16
Nucleolipid, 2.10
31
4
11

These results correlate nicely with the recently reported anti-cancer effects of the
amphiphilic D-(KLAKLAK)2-phospholipid liposome formulation which enhanced the
cytotoxicity of the killer peptide sequence within the A549 lung cancer cells and within the drugresistant lung cancer A549/Taxol cell line [30]. Thus, the amphiphilic palmitamide or nucleolipidderived D-(KLAKLAK)2-AK sequences represents an interesting class of bioconjugates that have
served to potentiate the cancer cell death response of the native D-(KLAKLAK)2-AK within the
A549 lung cancer cell line. Furthermore, the cytotoxic selectivity for cancer cell lines over normal
tissues for bioconjugates 2.8 and 2.9 is unanticipated but may be introduced by the incorporation
of cancer cell targeting ligands [6,7,9,12-14].
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Figure 2.4. NCI 60 cancer cell line screen for determining growth inhibition and cytotoxic activity
for a single dose (2.13 M) treatment of nucleolipid-derived D-(KLAKLAK)2-AK, 2.8.
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Figure 2.5. NCI 60 cancer cell line screen for determining growth inhibition and cytotoxic activity
for a single dose (7.25 M) treatment of palmitamide-derived D-(KLAKLAK)2-AK, 2.9.
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Figure 2.6. NCI 60 cancer cell line screen for determining growth inhibition and cytotoxic activity
for a single dose (10 M) treatment of D-(KLAKLAK)2-AK, 2.7
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2.6 CONCLUSIONS
In conclusion, the synthesis, characterization and anti-cancer activity of a new class of
killer peptide bioconjugates are reported in this chapter. The peptide bioconjugates were found to
be more hydrophobic relative to the native sequence. Moreover, the peptide bioconjugates
displayed α-helical structures and cationic nanoparticle formulations that were contributive
towards their anti-cancer activities. Within a NCI-60 cancer cell line screen, the peptide
bioconjugates displayed enhanced cell death activity relative to the native sequence within the
human A549 lung cancer cell line. These results validates the anti-cancer utility of the new
amphiphilic peptide bioconjugates and paves the way for a cancer cell biology study that may
ultimately unveil their mechanism of action. Moreover, the development of a key reductive
amination procedure for making nucleolipids provides an opportunity for the generation of a
diversity oriented synthesis approach. The latter is envisioned for making a library of functionally
diverse nucleolipids for their incorporation into a lead, such as the D-(KLAKAK)2 sequence, and
for improving its structure-function properties in cancer cell types. Moreover, the peptide
nucleolipid bioconjugate may also be functionalized with cancer-targeting peptide sequences for
the development of a selective anti-cancer approach. The latter is of current research interest and
some preliminary work detailing their development is presented in Chapter 3 of this thesis.

2.7. EXPERIMENTAL SECTION
General Methods:
All non-aqueous reactions were performed under inert atmosphere (nitrogen) unless
otherwise specified. All glassware was cleaned and stored in a pre-heated oven (160 oC) for drying
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and cooled in a dessicator prior to use. Anhydrous solvents and reagents were purchased from
Aldrich (St. Louis, MO) and used as received. Analytical thin-layer chromatography (TLC) was
performed on aluminum-backed silica gel plates (Merck 60 F254). TLCs were visualized under
UV shadowing (260 nm) or staining (10% H2SO4/MeOH). Compound purification using silica gel
chromatography was performed on a 230-400 mesh silica (Sorbent Technologies). Melting points
were obtained on a Thermo Melt apparatus. Specific rotations measurements were recorded on a
DigiPol 781 Automatic Polarimetry (Rudolph Instruments, Fairfield, NJ, USA) and collected as
an average of five measurements per compound. Data are reported as follows: [α]λ temp,
concentration (c in g/100 mL), in Acetone, MeOH, DCM or CHCl3. Molecular weights were
measured as direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ionsource in positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Infrared (IR)
spectra were obtained on a Nicolet 4700 FT-IR (ThermoElectron Co.) coupled with OMNIC
software (driver version: 7.1). The compounds were deposited on a KBr plate with the cast film
technique and the data was collected as an average of 3 scans in wavenumbers (cm-1). Nuclear
magnetic resonance spectra (1H,

13

C, COSY NMR) were recorded on an Varian Inova NMR

AS500 spectrophotometer. The NMR spectra were obtained at ambient temperature using an
indirect pulse-field gradient (ID-PFG) probe. The obtained data was processed using VNMRJ
software (version 2.2). The 1H and 13C assignments were based on gCOSY and gHMQC NMR
correlation experiments.
Synthesis:
3’-O-(allyl)-5’-O-(dimethoxytrityl) thymidine (2.2): To a suspension of 60% NaH (220 mg, 9.19
mmol) in anhydrous THF (20 mL) under argon at 0 °C was added 5’-O (dimethoxytrityl) thymidine
(2 g, 3.67 mmol). After sonication for 20 min, allyl bromide (792 μL, 9.17 mmol) was added and
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the reaction mixture was stirred at r.t. for 3 h. The mixture was poured into saturated NaHCO3 (40
mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were then washed with
brine (30 mL), dried over MgSO4, filtered and concentrated. Purification by flash column
chromatography (EtOAc–petroleum ether, 1:1 v/v, 1% Et3N) afforded 3’-O-(allyl)-5’-O(dimethoxytrityl)thymidine as a white solid; yield: 1.65 g (87 %); m.p. 83 °C. [𝛼]23
589 : +15.29 (c
0.01, Acetone). Rf = 0.44 (EtOAc–petroleum ether, 7:3 v/v). IR (KBr) υmax (cm-1) = 3182.1,
3059.1, 2929.9, 2836.8, 1693.4, 1607.7, 1582.3, 1508.9, 1464.5, 1364, 1273.5, 1251.1, 1177.1,
1105.4, 1063.1, 1033.5, 915.8, 829.1, 791.1, 755.8, 727.0, 702.1.1H NMR (500 MHz, acetone-d6):
δ = 1.52 (s, 3H), 2.42 (m, 2H), 3.43 (m, 2H), 3.82 (s, 6H), 4.07 (m, 2H), 4.10 (d, J = 3.0 Hz, 1H),
4.40 (t, J = 3.0 Hz, 1H), 5.17 (dd, J = 1.5, 10.5 Hz, 1H), 5.29 (dd, J = 1.5, 17.25 Hz, 1H), 5.93
(m, 1H), 6.33 (dd, J = 6.0, 8.0 Hz, 1H), 6.94 (d, J = 8.5 Hz, 4H), 7.28 (t, J = 7.5 Hz, 1H), 7.35–
7.41 (m, 6H), 7.52 (d, J = 7.0 Hz, 2H), 7.64 (d, J = 1.0, 1H). 10.03 (bs, 1H). 13C NMR (126 MHz,
acetone-d6): δ = 11.34, 37.36, 54.69, 63.97, 69.76, 79.04, 83.79, 84.49, 86.68, 110.2, 113.2, 116.1,
126.9, 127.9, 128.2, 130.1, 135.0, 135.5, 135.7, 135.8, 145.0, 150.4, 151.7, 158.9, 163.4, 179.2.
ESI MS (m/z) calculated for C34H36N2O7 [M+Na], 607.2; found 607.2.

3’-O-(formylmethyl)-5’-O-(dimethoxytrityl) thymidine (2.3): To a solution of 2.2 (1.63 g, 2.79
mmol) in a mixture of acetone–H2O (12 mL, 3:1 v/v) was added NMO (0.65 g, 5.58 mmol) and a
solution of 2.5% OsO4 in t-BuOH (1.8 mL). The mixture was stirred at r.t. for 2 h, then treated
with Na2S2O5 (0.98 g, 5.15 mmol) and stirred for 30 min. The reaction mixture was then treated
with H2O (50 mL) and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined
organic layers were washed with brine (100 mL), dried over MgSO4, filtered and concentrated.
The residue was dissolved in a mixture of acetone phosphate buffer pH 7 (22 mL, 3:1 v/v), and
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NaIO4 (1.50 g, 7.02 mmol) was added. The mixture was stirred at r.t. for 2 h, and then filtered, and
the precipitate was washed with EtOAc (50 mL). The separated aqueous layer was extracted with
EtOAc (2 × 50 mL) and then the combined organic layers were washed with brine (100 mL), dried
over MgSO4, filtered and concentrated. The crude product 3’-O-(formylmethyl)-5’-O(dimethoxytrityl) thymidine (solid; 1.50 g, 84%) was used directly as recovered. m.p. 123 °C.
-1
[𝛼]23
589 : +3.61 (c 0.80, acetone). Rf = 0.55 (CH2Cl2–MeOH, 9:1). IR (KBr) υmax (cm ) = 3307,

3066.8, 3007.3, 2953.4, 2929.6, 2856.5, 1736.7, 1698.6, 1660.3, 1610.8, 1557.2, 1509.6, 1485.4,
1445.8, 1382.6, 1300.8, 1253.5, 1217.4, 1176.1, 1109.9, 1072, 1034.8, 1002.6, 968.5, 936.6, 890.7,
863.6, 755.8, 704.6, 667.9 1H NMR (500 MHz, DMSO-d6): δ = 1.44 (s, 3H), 2.29-2.38 (m, 2H),
3.36 (dd, J = 3.0, 10.8 Hz, 1H), 3.45 (dd, J = 3.0, 10.8 Hz, 1H), 3.79 (s, 6 H), 4.06–4.10 (m, 2H),
4.18 (d, J = 2.5 Hz, 1H), 4.24 (d, J = 6.0 Hz, 1H), 6.19 (t, J = 2.0 Hz, 1H), 6.91 (dd, J = 1.0,
9.30 Hz, 4H), 7.23–7.28 (m, 7H), 7.40 (d, J = 7.0 Hz, 1H), 7.52 (d, J = 1.5 Hz, 1H), 9.55 (s, 1H),
11.4 (s, 1H). 13C NMR (126 .9 MHz, DMSO-d6): δ = 12.1, 14.5, 14.6, 21.2, 36.8, 39.4, 39.6, 39.7,
40.0, 40.1, 40.2, 40.4, 55.5, 60.2, 64.2, 74.7, 80.4, 83.3, 84.1, 84.2, 87.0, 110.2, 114.0, 113.7,
127.2, 128.1, 128.4, 130.1, 130.2, 135.6, 135.8, 136.0, 145.1, 151.0. ESI MS (m/z) calculated for
C33H34N2O8 [M+H], 586.2; found 586.2.

3’-O-(hexadecylaminoethyl)-5’-O-(dimethoxytrityl) thymidine (2.4): The starting material 2.3
(250 mg, 0.04 µmol) and 1-hexadecylamine (194 mg, 0.036 µmol) were dissolved in 3 mL of dry
THF. The reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (80
mg, 0.05 µmol, 1.5 equiv) was added to reaction mixture and stirred for 4 hrs. The reaction was
then concentrated in vacuum and purified by flash column chromatography using
EtOAc:Petroleum ether (6:4 v/v) to yield a white foamy product 2.4 in 43% yield. m.p. 70 °C.
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-1
[𝛼]23
589 : +9.11 (c 0.01, DCM). Rf = 0.50 (EtOAc–petroleum ether, 6:4 v/v). IR (KBr) υmax (cm ) =

3168.8, 3060.7, 2924.4, 2853.1, 2421.0, 1843.9, 1791.9, 1771.9, 1761.2, 1750.2, 1733.4, 1691.9,
1678.5, 1635.7, 1607.4, 1583.0, 1550.2, 1540.5, 1510.6, 1467.2, 1418.9, 1363.3, 1295.9, 1275.0,
1251.7, 1177.1, 1100.7, 1035.5, 964.0, 902.1, 829.4, 790.9, 754.8, 727.2, 702.0, 585.3, 492.7,
418.6. 1H NMR (499.84 MHz, CD2Cl2): δ = 0.91 (t, J = 7.0 Hz, 3H), 1.30 (t, J = 10.5 Hz, 28H) ,
1.50 (d, J = 12.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H), 2.46 (t, J = 6.0 Hz, 1H), 2.81 (d, J = 8.0
Hz, 1H), 3.00 (m, 2H), 3.33 (m, 1H), 3.44 (d, J = 11 Hz, 1H), 3.64 (m, 1H), 3.75–3.83 (m, 8H),
4.11 (dd, J = 2, 14.5 Hz, 1H), 4.21 (d, J = 5.0 Hz, 1H), 6.29 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m,
7H), 7.41 (d, J = 10.0 Hz, 2H), 7.46 (s, 1H). 13C NMR (125.6 MHz, CD2Cl2): δ = 22.6, 25.7, 25.8,
26.5, 29.1, 29.3, 29.4, 29.5, 29.6, 31.9, 53.0, 53.1, 53.4, 53.6, 53.8, 55.2, 55.3, 111.1, 113.2, 128.0,
130.0, 131.0, 135.3, 135.4, 158.9. ESI MS (m/z) calculated for C49H69N3O7 [M+H], 812.5; found
812.1

3’-O-(hexadecylaminoethyl)-thymidine (2.5): A solution of 3% TCA in DCM (10 mL) was
added dropwise at room temperature to 2.4 (100 mg, 0.123 mmol). The reaction was continued for
3 hr, the mixture was concentrated and loaded directly onto a column chromatography for
purification. The crude was purified (EtOAc:Petroleum ether, 3:2 v/v) to obtain >99% of a white
foamy product. m.p. 79 °C. [𝛼]23
589 -3.088 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether,
6:4). IR (KBr) υmax (cm-1) = 3632.9, 3572.0, 3410.1, 2923.6, 2853.2, 2424.5, 1733.4, 1709.2,
1703.0, 1692.0, 1678.0, 1665.7, 1659.0, 1642.3, 1468.4, 1378.1, 1276.8, 1098.1, 821.3, 775.2,
675.1. 1H NMR (499.9 MHz, DMSO-d6): δ = 0.87 (t, J = 6.75 Hz, 2H), 1.24 (s, 19H), 1.60 (bs,
1H), 1.79 (s, 3H), 2.14 (d, J = 6.5 Hz, 1H), 2.22-2.25 (m, 1H), 2.52 (s, 2H), 2.69 (d, J = 5.0 Hz,
1H), 2.76 (t, J = 5.25 Hz, 1H), 2.90 (t, J = 4.25 Hz, 2H), 3.60 (s, 1H), 3.70 (s, 1H), 4.0 (m, 1H),
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4.10 (d, J = 3.0 Hz, 1H), 6.51 (bs, 1H), 6.14-6.17 (m, 1H), 7.71 (s, 1H), 11.2 (s, 1H). 13C NMR
(126.9 MHz, DMSO-d6): δ = 12.7, 14.3, 14.4, 22.5, 24.9, 26.8, 29.0, 29.1, 36.6, 52.0, 53.2, 62.0,
64.4, 68.0, 80.2, 80.2, 80.3, 84.2, 84.3, 84.8, 84.9, 85.0, 110.0, 136.3, 136.4, 151.0, 164.1, 165.2.
ESI MS (m/z) calculated for C28H51N3O5 [M-H], 509.7; found 510.5.

3’-O-(hexadecylaminoethyl)-5’-carboxy-thymidine (2.6): To a solution of 2.5 (124 mg, 0.258
mmol) in CH2Cl2 (1.3 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO)
(9 mg, 0.06 mmol), and iodobenzene diacetate (BAIB) (184 mg, 0.570 mmol) at room temperature.
After the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 140 L) was added to the
reaction mixture and stirred for 24 h. After evaporation of the solvent, the residue was purified by
flash chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in
1
50% yield. [𝛼]23
589 (c 0.01, DCM), Rf = 0.20 (CHCl3: MeOH 9:1 v/v). H NMR (499.8 MHz,

DMSO): δ= 1.14 (t, J = 6.75 Hz, 3H), 1.56 (t, J = 13.2 Hz, 30H), 2.79-2.80 (m, 7H), 3.28-3.37
(m, 1H), 3.6 (bs, 1H), 3.98-4.05 (m, 2H), 4.44-4.45 (m, 1H), 4.51 (d, J = 1.5 Hz, 1H), 6.43-6.46
(m, 1H), 9.37 (s, 1H), 11.46 (bs, 1H). 13C NMR (125.69 MHz, DMSO-d6): δ= 13.0, 14.3, 22.5,
26.2, 27.0, 29.1, 29.5, 31.7, 39.5, 39.6, 40.0, 40.02, 40.1, 40.2, 40.3, 40.5, 83.2, 84.4, 86.0, 109.0,
139.0, 151.0, 164.4, 173.4. ESI MS (m/z) calculated for C28H49N3O6 [M-H], 522.3; found 522.4

Solid phase peptide synthesis:
Synthesis of peptides was performed on a PSI 200 Peptide Synthesizer (Peptide Scientific
Inc.) on a Rink amide poly(ethylene glycol) resin (Nova PEG, 0.47 mmol/g). Fmoc-D-amino acids
(3 eq.) were dissolved in DMF (4 mL) along with NMM (6 eq.) and HCTU (3 eq.). The reaction
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mixture was agitated for 5 min and added to the solid support for automated coupling and
deprotection. Coupling times were set to 20 min followed by deprotection of the Fmoc protecting
group (30 min) with 20% piperidine in DMF. Washing (MeOH and DMF) and drying of the
peptide bound support with N2(g) were accomplished prior to the recovery of the peptide bound to
resin. At the N-terminus, Fmoc-aminohexanoic acid (Ahx, 3 eq.) was coupled and Fmocdeprotected. Labeling of the Ahx-peptide N-terminus with fluorescein isothiocyanate (FITC, 1.1
eq.) in pyridine:DMF:DCM (12:7:5 v/v/v) was accomplished in the dark, overnight at room
temperature. Following synthesis, peptide cleavage from the solid support and deprotection of the
side-chain protecting groups were accomplished with concentrated trifluoroacetic acid (TFA,
95%) with minimal addition (5%) of reaction scavengers (i.e. H2O, triethylsilane). The cleavage
and deprotection reaction was completed in 2 hr at room temperature. Peptide samples were
concentrated, precipitated in cold diethyl ether, and isolated as white pellets for LC/MS analyses
and purification.
Solid-phase bioconjugation:
Solid-phase bioconjugation of peptide nucleolipid and palmitamide were performed on an oil bath
reaction apparatus with stirring block. Rink amide poly(ethylene glycol) resin (Nova PEG, 0.47
mmol/g) was transferred to a reaction vessel and swollen with 500 µl, DMF at 60 ºC for 2 hr. The
resin was filtered, washed and dried under N2(g) prior to the reaction. Nucleolipid or palmitamide
(3 eq.) were added in DMF (500 µl) along with NMM (6 eq.) and HCTU (3 eq.). The reaction
mixture was preactivated for 7 min before slowly added and agitated for 14 h at 60 ºC with peptide
bound to solid support. Coupling times were set at 20 min followed by deprotection of the Fmoc
protecting group (30 min) with 20% piperidine in DMF. Washing (MeOH, DMF and DCM) and
drying of the peptide bound support with N2(g) were accomplished prior to the recovery of the
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peptide bound to resin. Labeling of the Ahx-peptide N-terminus with fluorescein isothiocyanate
(FITC, 1.1 eq.) in pyridine:DMF:DCM (12:7:5 v/v/v) was accomplished in the dark, overnight at
room temperature. Following synthesis, peptide cleavage from the solid support and deprotection
of the side-chain protecting groups were accomplished with concentrated trifluoroacetic acid
(TFA, 95%) with minimal addition (5%) of reaction scavengers (i.e. H2O, triethylsilane). The
cleavage and deprotection reaction was completed in 2 h at room temperature. Peptide samples
were concentrated, precipitated in cold ether, and isolated as white pellets for LC/MS analyses and
purification.
Characterization of peptides by LC/MS:
Crude peptide pellets were dissolved in MeOH/H2O (50:50 v/v, 1 mL) for LCMS analyses.
Sample analyses were performed on an Agilent 1100 series ESI-LCMS with a single quadrupole
mass analyzer and LC conditions used a linear binary gradient 20-80% or 2-82% MeCN/H2O,
0.1% FA, over 17 min at 25°C. Analytical RP-HPLC was performed using a Waters 2695
Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) using a linear binary gradient, 2080% or 2-82% MeCN/H2O, 0.1% FA, over 17 min at 25°C, with a 1 mL/min flow rate and
detection at 220 nm and 260 nm. Samples collected after purification were lyophilized to a white
solid and re-dissolved in 50:50 v/v H2O:MeOH to confirm purity and identity by LCMS analyses.
Circular Dichroism (CD) Spectroscopy:
Samples were prepared 12-16 hr ahead of time in H2O:TFE (50:50, v/v, 1 mL) and stored
at 5 ºC. CD spectra were collected as an average of 3 scans on an Aviv Circular Dichroism (CD)
spectrophotometer (Model: 62A DS) from 190-260 nm, using 1 nm bandwidth and 0.5 min step
size at 25 oC. Samples were blank corrected, the data was smoothed and converted to molar
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ellipticity values from the equation [θ] = θ /cl, where θ is the molar ellipticity (mdeg), c is the
molar concentration of the peptides (12.5 µM) and l is the path length of the cell (1 cm). The data
was imported into Microsoft Excel and the CD spectra were plotted in terms of molar ellipticity
vs wavelength.
UV/Vis Spectroscopy:
The final concentrations of the peptide solutions was determined by UV/Vis
spectrophotometry at 214 nm ( value of peptides and calculated from the equation:
214 = (peptidebond)(npeptidebonds) + Σ (aminoacid(i))(naminoacid(i)).
The analyses were conducted on an 8452A Diode Array Spectrophotometer from Hewlett Packard,
with wavelength range set from 190 – 600 nm with maximum absorption collected at 220 and 260
nm in addition to 490 nm for the FITC-labeled peptides. Peptide concentrations were standardized
at 12.5 M.
Log P values were measured via octanol partitioning by a modification of the shake-flask
method. An aliquot (200 L, 0.16 mM) of the FITC-labeled peptide samples in Tris buffer (10
mM, pH 7.4) and 1-octanol (200 L) were added to a 0.5 mL micro tube. Samples were vortexed
(1 min) and centrifuged. An aliquot of each layer (150 L) was removed and diluted (850 L, 3:1
v/v methanol:Tris or methanol:octanol) to a final composition of 3:1:1 v/v/v methanol:octanol:Tris
buffer. The aqueous layer was diluted (30 and a series of three serial dilutions were prepared
for each phase. The log of the partition coefficient (FITC490nm of the organic layer vs. FITC490nm
of the aqueous layer) yielded log P values according to UV absorption measurements made at 490
nm. For compounds with very low lipophilicity (log P ≤ 2.3), the volume of the octanol and water
was increased from (100 to 125 L), and the absorbance of the octanol layer was measured without
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any additional dilutions. This procedure was repeated a minimum of three times per sample to
calculate the mean log P and standard error. All absorbance measurements used were within the
linear range of the instrument and blank corrected with Tris buffer and distilled water.
Dynamic Light Scattering (DLS):
DLS measurements were performed on Malvern Zetasizer (Malvern Instruments Limited
ZEN3600). All samples were diluted with pico pure water by ratio of 1:1, 1:4, 1:8, and 1:16.
Samples were sonicated for 15 minutes before measurement. Results were chosen from the major
population of the highest quality measurement.
Transmission Electron Microscopy (TEM):
Dilute samples used for DLS measurements were mixed in a 1:1 ratio with 1% uranyl
acetate, sonicated for 10 minutes. An aliquot (5 µL) was put on a carbon film coated copper grid,
300 mesh (electron microscopy sciences, Hatfield, PA) and the excess solution was removed
immediately using absorbent paper. The grids were dried overnight and viewed under the
transmission electron microscope (JEOL, model JEM-1200 EX). Images were taken with a SIA–
L3C CCD camera (Scientific Instruments and Applications, Inc.) using the software Maxim DL5
(Diffraction Limited, Ottawa, Canada).
Cell Viability:
NCI 60 testing is performed in two parts: first a single concentration is tested in all 60 cell
lines at a single dose of about 10-5 molar or 15 µg/ml. If the results obtained meet the selection
criteria, then the compound is tested again in all 60 cell lines in 5 x 10 fold dilutions with the top
dose being about 10-4 molar or 150 µg/ml.
Concentration Requirements – 1-dose/cancer in vitro program
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Peptide samples were prepared in DMSO:glycerol 9:1 v/v at a concentration of about 4
mM for the one dose assay and about 40 mM for the 5-dose assay. In both cases the solution is
diluted 1:400, giving a High Test concentration of about 10 or 100 µM, respectively.
Volume requirements – Pre-screen/cancer in vitro program

The cancer screen requires 100 µL for 1 log, 5-dose dilutions of regular compounds and
75 µL for 1-dose testing. 1-dose testing is done at 1/10th the high concentration of 5-dose testing,
so the volume requirement is 210 µl + 20% at 40 mM for compounds with molecular weights or
210 µL + 20% at 60,000 μg/ml = 250 µL for compounds without molecular weights
(macromolecules) (i.e. less than 10 mg for MW = 1000 or 15 mg for compounds tested as
weight/volume).
For 1-dose 60 cell testing: On the day of or the day before drug addition to growing cells
in tissue culture, a strip of standards (Adriamycin, NSC 123127 prepared and stored the same as
the compounds) is added to the detachable well plate, and 90 µL DMSO is added to each well (4
mM solution), and mixed/sonicated and 75 µL is transferred, using a 12 channel hand pipettor, to
a 12 channel reservoir plates (column plates), which is sealed and stored under nitrogen in a
desiccator box until delivered to the testing lab. The labels are placed at the right and the left of
the front of the reservoir plate. It will be the first and the last NSC number in the row. Rows are
transferred from detachable plate to columns 3-12 of column plates. Plates are sealed and stored
under nitrogen no more than 24 hours prior to drug addiction.
Interpretation of One-Dose Data
The one-dose data will be reported as a mean graph of the percent growth of treated cells
and will be similar in appearance to mean graphs from the 5-dose assay. The number reported for
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the one-dose assay is growth relative to the no-drug control, and relative to the time zero number
of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality
(values less than 0). This is the same as for the 5-dose assay, described below. For example, a
value of 100 means no growth inhibition. A value of 40 would mean 60% growth inhibition. A
value of 0 means no net growth over the course of the experiment. A value of -40 would mean
40% lethality. A value of -100 means all cells are dead. Information from the one-dose mean graph
is available for COMPARE analysis.
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STRUCTURE-ACTIVITY
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3.1 GENERAL INTRODUCTION
Nucleolipid bioconjugates have a wide range of applications including gene therapy,
medicinal chemistry and for the formulation of biomaterials for the development of
biotechnologies [1,2]. Their exceptional utility stems from an amphiphilic structure which
facilitates self-assembly into supramolecular nanoparticle formulations in aqueous and organic
solutions [3]. The structural features of nucleolipid bioconjugates includes a nucleoside core that
may participate in H-bonding interactions and hydrophobic lipid appendages which may facilitate
self-assembly through non-polar interactions. Moreover, nucleolipids may be functionalized with
reactive functional groups, including carboxylic acids that may participate in amide couplings,
azide and alkynes that can be used for dipolar cycloaddition chemistry in addition to the
incorporation of a wide range of electrophiles that may be prone towards nucleophilic substitution
or cross coupling reactions.
For example, an amino acyl nucleolipid was synthesized following an optimized EEDQcoupling strategy in which a reactive 5’-carboxy derived guanosine derivative was effectively
coupled to Lys(Boc)CO2Me [4]. The subsequent deblocking of the 2’ and 3’-CBz protecting
groups by hydrogenolysis followed by esterification of the 2’ and 3’-OH groups with palmitoyl
chloride afforded the aminoacylnucleolipid. The side-chain Lys(Boc) protecting group was
removed using acidic conditions to afford a partially protected cationic aminoacyl nucleolipid that
showed the ability to bind to GRP78 DNA and elicit selective and potent cell death (>90%) in a
SR leukemia cell line at 10 M [4]. The free-form guanosine aminoacyl nucleoplipids retain the
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ability to form stable G-tetraplexes in solution [5], while chelating with Li+ and K+ metal ions.
Interestingly, the self-assembled amphiphiles also produced H+/OH- ion flux in the presence of a
pH gradient making them potentially useful transporter ligands [5]. In anti-proliferative assays in
a selected panel of cancer cell lines, the nucleolipids showed modest activities (IC50: 17 - >103
µM) in the MCF-7 breast cancer cells [5]. Similarly, a cationic aminoacyl surfactant was formed
through a multi-step synthesis strategy, ultimately featuring Mitsonoubu chemistry which yielded
the reactive 3’-azido xylouracil derivative which was subsequently reduced to the free amino and
coupled to N-Boc-Pro using carbodiimide coupling conditions [6]. Carbodiimide couplings were
also used to functionalize the 2’-OH with oleic acid and the 5’-OH with a poly(ethylene) glycol
chain. The deprotection of the Boc group yielded a cationic amphiphile which formed micelles in
water and produced weak activities (IC50: 19 – 98 µM) relative to the control cetyl
triethylammonium bromide (CTAB) in a panel of human, rat and murine cell lines [6]. The
biological activity of the aminoacyl nucleolipid, was found to occur at concentrations nearing its
critical micelle concentration (cmc: 40 µM), underscoring the importance of a self-assembled
nanoparticle formulation for biological activity. Moreover, nucleolipid bioconjugates have been
used in gene delivery applications [7,8].

For example, synthetic polycationic nucleolipids

generated by carbonyldiimidazole couplings have been combined siRNA for the formation of
stable ionic complexes that facilitated delivery and release of siRNA within HeLa cells for
Vasuclar Endothelial Growth Factor (VEGF) knockdown [7]. The spermine derived amino acyl
nucleolipid was found to effectively transfect siRNA (>90% VEGF knockdown) which ultimately
led to apoptosis (~20%) in HeLa cells. The arginine-linked nucleolipid synthesized from a 1,3dipolar cycloaddition formed stable ionic complexes with anti-VEGF siRNA resulting in potent
VEGF knockdown (>90%) which paralleled the Lipofectamine-based siRNA transfections in
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HeLa cells [8]. The glycosyl nucleolipids have also formed an interesting class of amphiphiles. In
a relevant study, a glycosyl nucleolipid was synthesized by the Huisgen copper catalyzed azidealkyne 1,3-dipolar cyloaddition reaction which also facilitated the incorporation of alkyne-derived
fatty alcohols, steroids, terpenoids, fatty esters, amides and fluorinated amides [9]. The glycosyl
nucleolipids exhibited complementary H-bonding, - stacking and hydrophobic interactions
which contributed to their cytotoxicities (>70%) even after 72 h incubation with the human
hepatocarcinoma (Huh-7) cell line. Interestingly, the amphiphiles formed hydrogels with
distinctive supramolecular self-assemblies, including nanofibers, spheres and semitubular objects
that were speculated to contribute to their cytotoxicities. Therefore, functionally diverse
nucleolipids have shown the ability to self-assemble into amphiphilic supramolecular structures
that were found to be contributive to their anti-cancer activities.
Additional nucleolipids containing various modifications are represented in Figure 3.1.
The nucleotide-based amphiphiles (3.1) were formed from an extension of phosphoramidite
chemistry, by tetrazole-mediated couplings with fatty long chain alcohols [10]. The resulting
amphiphiles displayed the capabilities of forming lamellar-type structures held together by Hbonding interactions as discerned from FT-IR spectroscopy and X-ray diffraction studies. In a
related example, uridine phosphocholine-based amphiphiles were prepared with myristic, palmitic,
stearic, arachidic and oleic acids, 3.2 [11]. TEM imaging revealed the formation of small,
unilamellar vesicles and nanofibers capable of entrapping DNA for potential gene delivery
applications. More specifically, a uridine based nucleolipid, 3.3, was prepared via a synthetic
strategy featuring nucleophilic displacement of a reactive 5’-tosylate with trimethylamine to form
the quaternary ammonium tosylate salt. At the 2’ and 3’-OH groups, carbodiimide couplings
installed the dioleolyl groups. The cationic nucleolipid formed worm-like structures in aqueous
76

solution and formed multilamellar structures with calf thymus DNA, which was found to be
intercalated in between the lipid bilayers [12]. In a similar application, a phosphocholine
nucleolipid, 3.4, was synthesized in a 4-step procedure and was found to effectively form vesicles
with plasmid DNA [13]. The ability for cationic amphiphilic nucleolipids to readily condense
nucleic acids into stable nanoparticle formulations paves the way for gene delivery applications in
gene therapy, biotechnology and in molecular cell biology.
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Figure 3.1. Synthetic nucleolipids scaffolds (A) deoxythymidine palmitoylphosphate [10] (B) 1,2dipalmitoyluridinophosphocholine (DPUPC) [11] (C) (N-[5’,(2’,3’-dioleoyl)uridine-N’,N’,N’trimethylammonium tosylate (DOTAU) [12] (D) O-ethyl-dioleylphosphatidylcholinium-uridine
(O-ethyl-DOUPC) [13].
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The nucleolipids are based on non-ionic, zwitterionic, and ionic structures that are adaptive
towards self-assembly and nanoparticle formulation. The alkylamine hydrophobic chain was also
found to play an important role in the self-assembly process. It provided hydrophobic character to
the amphiphile that resulted in the self-assembly of topologically defined structures (Figure 3.2).
Cryo-TEM reveals high resolution imaging of phospholipid nucleosides, including the selfassembly of polydisperse wormlike micelles for 1,2-dilauroyl-sn-glycerophosphatidyluridine
(DLPU) in aqueous solution (Figure 3.2 A) [18]. Spontaneous formation of helical structures has
also been observed for dimyristoyl-5’-phosphatidyldeoxycytidine (DMPcyt) (Figure 3.2 B). The
electron micrograph of the super helical strands served as proof of self-assembly and formulation
into discrete, well-defined structures [19]. Related examples include, a palmitoyl phosphate
nucleolipid, which was found to self-assemble into flat and aggregated motifs, the choline-based
nucleolipids produced quasi-spherical micelles, whereas the 5’-substituted nucleolipids produced
micelles, flexible cylindrical aggregates and bilayers based on alkylamine chain length. Short
chain alkylamines (e.g. (CH2)6 to (CH2)9) formed quasi-spherical micelles and long chain
alkylamine (e.g. (CH2)10 to (CH2)20) nucleolipids formed flat structures [14-19]. These examples
serve to illustrate the functionally diverse nature of amphiphilic nucleolipids. Synthetic methods
have not only facilitated their production but also improved their applications. As such, nucleolipid
bioconjugates form an interesting class of amphiphiles that retain the ability to self-assemble into
well-defined high-order nanostructure formulations for a wide range of applications. These include
but are not limited to their use as responsive biomaterials, as diagnostic and therapeutic probes.
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Figure 3.2. Phospholipid-nucleolipid self-assembly into higher-ordered nanostructures. TEM
images adapted from Allain, V.; Bourgaux, C.; Couvreur, P. Nucleic Acids Res. 2012, 40, 18911903.

3.2 CHAPTER OBJECTIVES
The synthesis, characterization and anti-cancer activity of a new class of killer peptide
bioconjugates was reported in Chapter 2. The nucleolipid derived D-(KLAKLAK)2-AK sequence
retained an amphiphilic, -helical structure which displayed greater anti-proliferative effects in a
selective panel of NSCLC when compared to the palmitamide derived peptide and the wild type
sequence. In the search for more potent peptide-based anti-cancer conjugates the development of
new and improved nucleolipid derived D-(KLAKLAK)2-AK sequences are desired. Towards this
goal, this chapter describes the diversity oriented synthesis of new peptide-nucleolipid conjugates
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for structure-activity relationship studies (SARs) against cellular tumor targets. Considering a
reductive amination approach was successfully developed for the synthesis of a hecadecylaminederived nucleolipid-peptide conjugate, this approach may be perfectly suitable for the
incorporation of various small, medium, large chain alkylamine, diamines, unsaturated amines or
polyamines for exploring SARs. More specifically, these modifications are expected to fine tune
the amphiphilic poly(cationic) -helical properties of the peptide nucleolipids. These requirements
are anticipated to improve binding and permeability across the lipid bilayer of malignant tumor
types. These characteristics are also anticipated to improve peptide accumulation at the
mitochondria that results in the dissipation of charge, the disruption of organelle integrity and the
release of pro-apoptotic executors that effect cancer cell death. The proposed mechanism of action
is described in Figure 3.3.

Figure 3.3. Proposed mechanism of action for the peptide nucleolipid bioconjugates.
The judicious selection of different alkyl amines, including methylamine and octylamine
was based on their capabilities to fine tune peptide hydrophobicity and to provide a comparative
study investigating the influence of alkyl chain length on peptide structure, biophysical and
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biological properties. Moreover, histamine modifications have also been incorporated for boosting
immune responses while acting as neurotransmitters by binding to the G-protein coupled histamine
receptor [14-16]. Thus, histamine derived peptide nucleolipids are expected to trigger multiple
biological responses in live cancer cells. Polyamines such as 1,3-diamino propane and spermine
are expected to generate poly(cationic) nucleolipids at physiological pH. This feature is not only
expected to facilitate peptide internalization and mitochondria localization but also in the delivery
of poly(anionic) cargo, such as in the delivery of siRNA for RNAi applications. Thus, this chapter
describes the diversity oriented synthesis strategy for the development of functionally diverse
carboxy-derived nucleolipids that may then be combined with the killer peptide sequence by our
well-established solid-phase bioconjugation approach. Peptide nucleolipid bioconjugates will be
analyzed and purified by LC/MS. Peptide biophysical studies will be determined by RP HPLC and
UV-Vis spectroscopy while CD spectroscopy will shed insights on the structural properties of the
bioconjugates. The anti-cancer screen of the bioconjugates will take place in collaboration with
Hackensack University Medical Center, under the supervision of Dr. Robert Korngold. Mariana
Phillips (PhD student in the Sabatino group located in the Department of Chemistry and
Biochemistry) will conduct cell based cytotoxicity studies in the selected tumor cells in order to
validate a lead peptide-nucleolipid bioconjugate. Taken altogether, these important SAR studies
are not only pivotal to the identification of peptide-nucleolipid combinations that can effect potent
cancer cell death, but also in the selection of a lead bioconjugate that can be functionalized with
cancer-targeting ligands for the selective treatment of tumors. The latter is a focus of current and
future studies aimed towards the development of selective and potent peptide anti-cancer drugs
(Chapter 4).

82

3.3

SYNTHESIS

AND

CHARECTERIZATION

OF

PEPTIDE-NUCLEOLIPID

BIOCONJUGATES.
3.3.1. RATIONAL DESIGN OF PEPTIDE-NUCLEOLIPID BIOCONJUGATES
The rational design of a library of peptide-nucleolipid bioconjugates was developed in this
study (Figure 3.4). The nucleolipid scaffold was designed with diverse functional groups
including alkylamines with varying chain lengths (e.g. methylamine, octylamine and
hexadecylamine) to explore the influence of hydrophobicity on peptide structure and activity.
Moreover, alkyl diamines and polyamines (e.g. diamino propane and spermine) were also included
as functional groups that were anticipated to bear polycations at physiological pH. The latter
encompasses an important requirement for cell permeability and mitochondrial localization that
ultimately results in cellular cytotoxicity [20]. Furthermore, cyclic amines such as histamine were
also included in our proposed design to fine-tune the amphiphilic nature of the nucleolipid while
potentially triggering interesting biological activities inside cells [21]. The functionally diverse
nucleolipids were also designed with a reactive 5’-carboxy group which would facilitate coupling
to the -amino group of the C-terminal Lys within the D-(KLAKLAK)2-AK sequence. At the Nterminus, the peptide sequence is lengthened by an aminohexanoic acid linker (AHx) which is
necessary for the efficient incorporation of the fluorescein isothiocyanate (FITC) fluorescent tag
for imaging biological activity inside cells [22]. In this manner, the newly designed D(KLAKLAK)2-AK nucleolipid bioconjugates (Figure 3.4) would serve to explore the influence of
structurally diverse nucleolipids on the biological activity of the killer peptide sequence. These
studies are not only important for determining structure-activity relationships but also in
identifying a lead that can be further optimized into an anti-cancer therapeutic.
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Figure 3.4. Design of killer peptide nucleolipid bioconjugates. Figure adapted from Rana, N.,
Huang, S.; Patel, P.; Samuni, U.; Sabatino, D. Bioorg. Med. Chem. Lett., 2016, 26, 3567–3571.

3.3.2. DIVERSITY ORIENTED SYNTHEIS OF NUCLEOLPIDS
The 3’-aldehyde derived thymidine, 3.5, was selected as the reactive precursor for the
diversity oriented synthesis of functionally diverse nucleolipids (Figure 3.5). In this synthesis
method, the reductive amination approach was optimized with functionally diverse amines for
yielding nucleolipids 3.6-3.10. The reductive amination with methylamine and octylamine
proceeded smoothly according to TLC. However, difficulties associated with extraction and
chromatographic purification limited yield recoveries. Nonetheless, the alkylamine-derived
nucleolipids, 3.6-3.7, were recovered in sufficient quantities (14-32% yields) for their conversion
into the desired 5-carboxy derived nucleolipids as described in Scheme 3.1. The histamine,
spermine and N-Boc diaminopropoane derived nucleolipids (3.8-3.10) proved more difficult to
make. In these cases, the formation of side products, presumably due to the reactive amino
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functionalities were detected by TLC and difficulties associated with recoveries following
extraction and purification resulted in low yields (8-20%). The isolated products were analyzed
and characterized by a combination of 1H, 13C NMR and mass spectrometry.

Figure 3.5. Diversity oriented synthesis of various nucleolipids by the reductive amination
approach.
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The diversity oriented synthesis strategy for the various nucleolipids developed in this
study is based on the reductive amination approach which ultimately yielded the 5’-carboxy
derived nucleolipids 3.16-3.20 (Scheme 3.1). Following quantitative removal of the 5’-DMT
group using trichloroacetic acid (TCA), a TEMPO-mediated oxidation reaction converted the 5’hydroxy group to the carboxylic acids, 3.16-3.20. Each reaction intermediates and the final
products were characterized by 1H and 13C NMR, IR spectroscopy and by MS to confirm purities
and identities for the incorporation of the 5’-carboxy derived nucleolipids 3.16-3.20 within the
killer D-(KLAKLAK)2-AK sequence.

Scheme 3.1. Solution phase synthesis of the 5’-carboxy derived nucleolipids, 3.16-3.20.

3.4 DESIGN, SOLID PHASE BIOCONJUGATION AND CHARACTERIZATION OF
(FITC)-AHX-D-(KLAKLAK)2-AK-NUCLEOLIPIDS
3.4.1. DESIGN OF NOVEL AHX-D-(KLAKLAK)2-AK-NUCLEOLIPIDS
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The novel peptide nucleolipids consist of trifunctional bioconjugates (Figure 3.6). They
contain an N-terminal AHx-linked FITC fluorophore for fluorescent imaging and detection
applications in live cancer cells. The D-(KLAKLAK)2 peptide encompasses the killer peptide
sequence while the C-terminal AK sequence contains a Lys(Dde) residue that can be removed
under orthogonal deprotection conditions to reveal the reactive side chain amino group for
bioconjugation. Solid phase bioconjugation of the support-bound D-(KLAKLAK)2-AK sequence
with the carboxy derived nucleolipids is anticipated to provide a small library of peptidenucleolipid conjugates for exploring structure-activity relationships in cancer.

Figure 3.6. Peptide-nucleolipid structures. The D-(KLAKLAK)2-AK peptide scaffold with
R1(red) = H or FITC, R2(blue) = Nucleolipid where R = CH3, (CH2)7CH3, (CH2)15CH3,
(CH2)3NH(CH2)4NH(CH2)3NH2, (CH2)3NH2, and histamine. All amino acids are in their Dconfiguration.
3.4.2. SOLID PHASE BIOCONJUGATION
The solid phase bioconjugation approach has been developed to actively couple potent and
reactive drug like molecules or biologicals onto the solid support e.g. resin, bead, or mica surface.
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A suitable solid support was first selected based on sequence compatibility and synthetic
efficiency. The poly(ethylene glycol) (PEG) based resins have proven to be especially useful in
the synthesis of lengthy and hydrophobic peptides that have the tendency to aggregate during the
solid phase synthesis procedure. The excellent swelling properties of PEG-based resins in organic
solvents such as DMF and acids such TFA have been shown to improve synthetic efficiency and
recoveries following solid phase peptide synthesis [24]. In our approach, the D-(KLAKLAK)2-AK
sequence was synthesized on the Rink amide PEG resin for generating C-terminal peptide amides.
The C-terminal Lys residue contained the Dde protecting group that has been shown to
orthogonally deblock using buffered hydroxylamine hydrochloride that promotes the
transamination reaction of the support-bound peptide sequence [25]. In our approach,
hydroxylamine hydrochloride was buffered and solubilized in imidazole and NMP/DMF,
respectively, for selectively unmasking the Lys side chain Dde group. This reaction was closely
monitored by LC-MS that produced 60-80% conversions on solid phase. An Fmoc protecting
group at the N-terminus directed the coupling of the 5’-carboxy-derived nucleolipids at the Cterminus Lys side chain amino group. A HCTU-mediated coupling reaction (Scheme 3.2) was
used to couple the nucleolipids to the support-bound peptide sequence. Following solid-phase
bioconjugation, Fmoc deprotection using basic piperidine followed by FITC coupling at the Nterminal AHx linker produced the FITC-labeled peptide-nucleolipid bioconjugates on solid phase.
Of note, peptide-nucleolipid bioconjugates were also produced without the FITC label. In these
cases, a portion of the Fmoc-AHx-D-(KLAKLAK)2-nucleolipid bound resin was Fmoc deblocked
followed by cleavage and deprotection of the bioconjugate from solid phase. The TFA-mediated
cleavage and deprotection conditions were also employed for isolating the FITC-labeled
bioconjugates from solid phase. Control peptides with and without the FITC/nucleolipids were
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also produced in order to determine the influence of the modifiers on peptide structure and
biological activities. The isolated peptide-nucleolipid bioconjugates were analyzed and purified
by RP HPLC (Table 3.2). The identities of the pure bioconjugates were confirmed by LC-MS for
SAR studies.

Scheme 3.2. Solid phase synthesis of FITC and non-FITC tagged D-(KLAKLAK)2-AK with
nucleolipids.
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a

b

c

d

Entry

Sequence
and
Number

Crude
Purity(%)

Isolated
Purity(%)

Isolated
Yield(%/mg)

M.W.
(g/mol)
Actual(e)

1

AHx-D(KLAKLAKKLAKLAK)AK-Methylamine
nucleolipid, 3.22
AHx-D(KLAKLAKKLAKLAK)AK-Octylamine
nucleolipid, 3.23
AHx-D(KLAKLAKKLAKLAK)AK-Histamine
nucleolipid, 3.24
AHx-D(KLAKLAKKLAKLAK)AK-Spermine nucleolipid,
3.25
AHx-D(KLAKLAKKLAKLAK)AK-1,3-diaminopropane
nucleolipid, 3.26
FITC-AHx-D(KLAKLAKKLAKLAK)AK-Methylamine
nucleolipid, 3.27
FITC-AHx-D(KLAKLAKKLAKLAK)AK-Octylamine
nucleolipid, 3.28
FITC-AHx-D(KLAKLAKKLAKLAK)AK-Histamine
nucleolipid, 3.29
FITC-AHx-D(KLAKLAKKLAKLAK)AK-Spermine nucleolipid,
3.30
FITC-AHx-D(KLAKLAKKLAKLAK)AK-1,3-diaminopropane
nucleolipid, 3.31

70

99

67/10

55

96

78

2

3

4

5

6

7

8

9

10

e

f

g

Z

RT
(min)
MeOH

RT
(min)
MeCN

533.6
(533.1)

4

10.6

9.7

80/9

446.3
(446.7)

5

11.2

8.9

95

79/12

386.0
(386.2)

6

9.3

5.7

83

96

80/9

576.5
(576.2)

4

12.0

10.1

90

97

54/7.5

544.4
(544.4)

4

11.9

7.4

85

>99

45/8

505.0
(505.7)

5

13.2

11.1

86

>99

60/9.5

524.8
(524.6)

5

15.0

12.3

90

>99

71/6

521.8
(521.0)

5

12.3

12.0

93

98

80/5.5

539.6
(539.2)

5

13.3

9.8

75

>99

73/7.8

641.4
(641.8)

4

15.0

14.5

Table 3.2. Characterization data of peptide nucleolipid bioconjugates. aCrude purities by RPHPLC at 220 nm. bIsolated purities by RP-HPLC at 220 nm using 2-80% MeOH/H2O with 0.1%
FA over 17 min. cIsolated yields based on the resin loading. dObserved mass (expected mass) as
[M+H]+/Z as detected by LCMS. eCharged state of the peptides as detected by LCMS in positive
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mode. fRetention times using 2-80% MeOH/ H2O with 0.1% FA over 17 min. gRetention times
using 2-80% MeCN/H2O with 0.1% FA over 17 min.

3.4.3. CHARACTERIZATION OF PEPTIDE NUCLEOLIPID BIOCONJUGATES
The hydrophilicities of the peptide bioconjugates were confirmed by RP HPLC (Figure
3.7). In our analysis, the histamine-derived peptide nucleolipid bioconjugate (3.24) eluted fastest
on the C18 RP HPLC column (rt: 9.3 min) during the acidic RP HPLC conditions (i.e. 2-80%
MeOH/H2O 0.1% FA). This result suggests that the heterocycle fine-tunes the amphiphilic nature
of the nucleolipid. Furthermore, the ionizable imidazole is also anticipated to be protonated during
the RP HPLC conditions further contributing to the polar, polycationic nature of the sequence. The
polyamine derived peptide-nucleolipid bioconjugates (3.25 and 3.26) proved to be most
hydrophobic and retained (rt: 12.0 min and 11.9 min, respectively) indicating that the lengthy,
aliphatic hydrocarbon polyamine chain of the nucleolipid provided a more non-polar contribution
to the bioconjugate. Presumably, this factor outweighs the polar contribution of the polycationic
polyamine using the same eluent gradient conditions on the C18 RP column. The methyl- and
octyl-amine derived peptide nucleolipids (3.22, 10.6 min and 3.23, 11.2 min, respectively) were
also found to be hydrophobic and retained sequences on the C18 RP column, albeit to a lesser
extent when compared to the polyamine-derived nucleolipid bioconjugates (3.25 and 3.26). Taken
together, the nucleolipids contribute variable effects on the polarity of the D-(KLAKLAK)2-AK
sequence that may influence their structure, formulation and biological activity in cell culture
conditions.

91

Figure 3.7. Comparative RP HPLC analysis of the nucleolipid-derived D-(KLAKLAK)2-AK,
bioconjugates (3.22-3.26).
Furthermore, UV-Vis spectroscopy confirmed the characteristic absorption bands of the
peptide bonds (λmax ~ 220 nm), thymine base (λmax ~ 260 nm) and the FITC label (λmax ~ 450 nm)
corresponding to the nucleolipid-derived D-(KLAKLAK)2-AK, bioconjugates (Figure 3.8).

Figure 3.8. Comparative UV-Vis spectroscopy (190-310 nm) of the nucleolipid-derived D(KLAKLAK)2-AK, bioconjugates (3.22-3.26) and (3.27-3.31).
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CD spectroscopy was then used to evaluate the secondary structures (if any) of the peptides
in H2O:TFE. The combination of H2O:TFE has served to mimic the amphiphilic lipid bilayer
microenvironment that may stabilize peptide secondary structures [26]. In this study, the methyland octyl-amine nucleolipid derived D-(KLAKLAK)2-AK sequence, 3.22 and 3.23, respectively,
displayed stable, α-helical secondary structure (40-65% helicity), while the histamine nucleolipid
derived D-(KLAKLAK)2-AK, 3.24, displayed enhanced helicity (65-76%) and the polyamine
nucleolipid derived D-(KLAKLAK)2-AK 3.25 and 3.26, demonstrated a less stable (<40%) α helical secondary structure (Figure 3.9). Many amphiphilic cell-penetrating peptides adopt αhelical secondary structures. This peptide motif may functions as a recognition site with other
membrane spanning proteins facilitating cellular permeability [27].

Figure 3.9. CD spectroscopy of the peptide-nucleolipid bioconjugates (3.22-3.26) in TFE:H2O
(1:1 v/v, 12.5 M).
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3.5. BIOLOGICAL ACTIVITIES OF THE NUCLEOLIPID-PEPTIDE BIOCONJUGATES
3.5.1. CYTOTOXICITIES IN MM1S MELANOMA CANCER CELLS
The cytotoxic activities of the nucleolipid-peptide bioconjugates (3.22-3.26) were
evaluated within the MM.1S human multiple myeloma B cell lymphoblast culture, known to be a
clinically relevant tumor model for evaluating the anti-cancer effects of new drug candidates [28].
The MM.1S cell culture and testing of the synthetic bioconjugates was accomplished by Mariana
Phillips and Chris Cultrara, PhD students in the laboratory of Dr. David Sabatino (Department of
Chemistry and Biochemistry, SHU). A Guava Nexin® Reagent (EMD Millipore) was used to
assess early and late-stage apoptosis by flow cytometry [29]. In this assay, the MM.1S cells were
incubated for 24 hours with the bioconjugates (3.22-3.26, 2.5 M in PBS buffer). After incubation,
the cells were centrifuged, washed and stained with the Guava Nexin® Reagent to determine the
MM.1S cells’ viability using flow cytometry. The results showed early and late stage apoptotic
events for the MM.1S cells when treated with the histamine-derived nucleolipid-peptide
bioconjugate 3.24, (Figure 3.10) making it a lead for further biological evaluation. The remaining
bioconjugates did not exhibit toxicity in this assay.
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Figure 3.10. Peptide-nucleolipid bioconjugate effects on the MM1S cells’ viability according to
the Guava Nexin Reagent using flow cytometry.
3.6 CONCLUSIONS
In conclusion, a versatile diversity-oriented synthesis approach for the generation of a small
library of novel peptide-nucleolipid bioconjugates is described in this chapter. The methodology
underscores a flexible and adaptive reductive amination approach for installing a variety of alkyl,
cyclic and polyamines into a nucleoside scaffold for formulating structurally diverse nucleolipids
for exploring SAR studies. The nucleolipids were functionalized with a reactive 5’-carboxy group
which facilitated bioconjugation on solid support with the cytotoxic D-(KLAKLAK)2-AK
sequence. The peptide-nucleolipid bioconjugates were found to exhibit tunable biophysical and
structural properties that were influenced by the nature of the nucleolipid group. In general, the
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bioconjugates maintained amphiphilic, -helical characteristics which were anticipated to
contribute to their biological activities in live cancer cells. A single dose (2.5 M) screen against
the MM.1S multiple myeloma cancer cells revealed a lead peptide that was contributive towards
early and late stage apoptotic events. This lead potentially encompasses a new class of peptidebased anti-cancer drugs.

3.7. EXPERIMENTAL SECTION
3.7.1. SYNTHESIS
5’-O-(dimethoxytrityl) 3’-O-(methylaminoethyl) thymidine [3.6]: The starting material 3.5
(200 mg, 0.34 mmol) and methylamine (11.2 µL, 0.32 mmol) were dissolved in 3 mL of dry THF.
The reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (26 mg,
0.41 mmol, 1.2 equiv) was added to reaction mixture and stirred for 4.5 hrs. The reaction was then
concentrated in vacuo and purified by flash column chromatography using EtOAc:Petroleum ether
(9:1 v/v) to yield a white foamy product 3.6 in 32% yield. m.p. 60 °C. [𝛼]22
589 : +12.11 (c 0.01,
DCM). Rf = 0.60 (EtOAc–petroleum ether, 9:1 v/v). IR (KBr) υmax (cm-1) = 5994.0, 5978.8, 5966.7,
5948.3, 5937.3, 5920.7, 5913.2, 5895.0, 5886.7, 5871.7, 5863.0, 5833.2, 5843.4, 5773.8, 5757.6,
5743.1, 5579.2, 5467.3, 5317.1, 5205.1, 5161.5, 5155.3, 5077.3, 5025.6, 4960.5, 3750.9, 3744.9,
3737.1, 3712.1, 2376.1, 2347.0, 1507.4, 1275.2, 764.2, 749.5. 1H NMR (499.79 MHz, CD2Cl2): δ
= 0.92 (t, J = 6.0 Hz, 3H), 1.34 (t, J = 12 Hz, 3H) , 1.50 (d, J = 12.0 Hz, 3H), 1.57 (s, 1H), 2.27
(m, 1H), 2.40 (t, J = 6.0 Hz, 1H), 2.78 (d, J = 8.0 Hz, 1H), 2.99 (m, 2H), 3.31 (m, 1H), 3.40 (d,
J = 11 Hz, 1H), 3.61 (m, 1H), 3.70–3.81 (m, 8H), 4.10 (dd, J = 2, 14.5 Hz, 1H), 4.20 (d, J = 5.0
Hz, 1H), 6.24 (m, 1H), 6.86 (m, 4H), 7.24-7.33 (m, 7H), 7.41 (d, J = 10.0 Hz, 2H), 7.50 (m, 1H).
C NMR (125.68 MHz, CD2Cl2): δ = 11.6, 37.3, 63.5, 72.3, 80.9, 83.5, 84.6, 84.7, 87.0, 110.9,
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111.2, 113.1, 113.3, 127.0, 128.0, 129.9, 130.0, 135.2, 135.2, 135.3, 135.5, 144.4, 144.5, 144.6,
150.3, 158.9, 163.4. ESI MS (m/z) calculated for C34H41N3O7 [M+H], 602.7; found 602.6.
5’-O-(dimethoxytrityl) 3’-O-(octylaminoethyl) thymidine [3.7]: The starting material 3.5 (200
mg, 0.340 mmol) and octylamine (54 µL, 0.323 mmol) were dissolved in 3 mL of dry THF. The
reaction was stirred for 30 min at room temperature and sodium cyanoborohydride (26 mg, 0.409
mmol, 1.2 equiv) was added to reaction mixture and stirred for 4.5 hrs. The reaction was then
concentrated in vacuo and purified by flash column chromatography using EtOAc:Petroleum ether
(6:4 v/v) to yield a white foamy product 3.7 in 14% yield. m.p. 67 °C. [𝛼]23.6
589 : +38.04 (c 0.01,
Acetone). Rf = 0.80 (EtOAc–petroleum ether, 6:4 v/v). IR (KBr) υmax (cm-1) = 2346.8, 1748.4,
1715.1, 1704.9, 1681.9, 1669.4, 1647.0, 1569.5, 1575.6, 1558.0, 1540.3, 1521.1, 1506.7, 1489.3,
1275.3, 1261.1, 764.2, 749.8. 1H NMR (499.84 MHz, CD2Cl2): δ = 1.10 (t, J = 7.0 Hz, 3H), 1.32
(t, J = 10.5 Hz, 16H) , 1.52 (d, J = 7.0 Hz, 3H), 1.50 (s, 1H), 2.21 (m, 1H), 2.42 (t, J = 7.0 Hz,
1H), 2.679 (d, J = 2.0 Hz, 1H), 3.00 (m, 2H), 3.33 (m, 1H), 3.42 (d, J = 7 Hz, 1H), 3.62 (m, 1H),
3.71–3.82 (m, 8H), 4.11 (dd, J = 2.0 Hz, 1H), 4.21 (d, J = 5.0 Hz, 1H), 6.29 (t, 1H), 6.90 (d, 4H),
7.22-7.32 (m, 7H), 7.53 (d, J = 10.0 Hz, 2H), 7.43 (s, 1H).
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C NMR (125.6 MHz, CD2Cl2): δ

=5.1, 7.7, 11.7, 21.9, 22.6, 25.7, 29.0, 31.6, 37.5, 47.0, 55.2, 62.4, 63.8, 72.2, 80.9, 92.4, 110.0,
111.1, 113.3, 128.0, 129.9, 132.2, 135.2, 143.0, 147.1, 150.2, 154.8, 158.8, 165.3, 178.7, 182.1,
217.6, 231.8. ESI MS (m/z) calculated for C41H54N3O7 [M+H], 699.8; found 699.9.
5’-O-(dimethoxytrityl) 3’-O-(histamineoethyl) thymidine [3.8]: The starting material 3.5 (200
mg, 0.340 mmol) and histamine (36 mg, 0.323 mmol) were dissolved in 3 mL of dry THF. The
reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (26 mg, 0.409
mmol, 1.2 equiv) was added to reaction mixture and stirred for 4 hrs. The reaction was then
concentrated in vacuo and purified by flash column chromatography using EtOAc:Petroleum ether
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(9:1 v/v) to yield a white foamy product 3.8 in 8% yield. m.p. 90 °C. [𝛼]23.8
589 : +204.4 (c 0.01,
DCM). Rf = 0.75 (EtOAc–petroleum ether, 9:1 v/v). IR (KBr) υmax (cm-1) = 3492.2, 2347.5, 2174.8,
1733.8, 1677.5, 1658.7, 1641.8, 1631.3, 1557.4, 1540.8, 1502.6, 1440.0, 1391.0, 1251.7, 1178.4,
1104.9. 1H NMR (499.9 MHz, CD2Cl2): δ = 1.0 (t, J = 4.0 Hz, 3H), 1.35 (m, 4H) , 1.50 (d, J =
12.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H), 2.46 (t, J = 6.0 Hz, 1H), 2.84 (d, J = 7.9 Hz, 2H), 3.00
(m, 2H), 3.34 (m, 1H), 3.47 (d, J = 11 Hz, 1H), 3.65 (m, 1H), 3.75–3.81 (m, 6H), 4.11 (dd, J = 2,
14.5 Hz, 1H), 4.80 (d, J = 5.0 Hz, 1H), 6.28 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m, 7H), 7.41 (d, J
= 10.0 Hz, 1H), 7.0 (s, 1H), 8.73 (m, 1H), 11.3 (m, 1H), 13.0 (m, 1H). 13C NMR (125.6 MHz,
CD2Cl2): δ = 7.7, 11.7, 22.6, 25.7, 29.0, 31.6, 55.2, 55.3, 62.4, 63.8, 80.9, 92.4, 110.0, 111.1,
113.3, 128.0, 129.9, 130.0, 135.2, 150.2, 158.8. ESI MS (m/z) calculated for C38H44N5O7 [M+H],
681.7; found 681.8.
5’-O-(dimethoxytrityl) 3’-O-(spermineoethyl) thymidine [3.9]: The starting material 3.5 (200
mg, 0.340 mmol) and spermine (66 mg, 0.323 mmol) were dissolved in 3 mL of dry THF. The
reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (26 mg, 0.409
mmol, 1.2 equiv) was added to reaction mixture and stirred for 4 hrs. The reaction was then
concentrated in vacuo and purified by flash column chromatography using EtOAc:Methanol (9:1
v/v) to yield a white foamy product 3.9 in 20% yield. m.p. 85 °C. [𝛼]23
589 : +35.5 (c 0.01, DCM). Rf
= 0.10 (EtOAc–Methanol, 9:1 v/v). IR (KBr) υmax (cm-1) = 5533.1, 5465.0, 3501.1, 3550.3, 3473.4,
3300.0, 2376.6, 2347.0, 1868.4, 1843.9, 1829.5, 1810.3, 1800.3, 1791.7, 1780.1, 1771.0, 1748.3,
1739.8, 1714.1, 1705.6, 1683.1, 1669.8, 1662.4, 1647.0, 1635.6, 1507.3, 1454.6, 1423.6, 1365.6,
1219.5, 1034.9. 1H NMR (499.84 MHz, CD2Cl2): δ = 1.0 (m, 3H), 1.30 (t, J = 10.5 Hz, 2H) , 1.38
(m, 4H), 1.48 (d, J = 10.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H), 2.46 (t, J = 6.0 Hz, 1H), 2.53 (m,
10H), 2.81 (d, J = 8.0 Hz, 1H), 3.00 (m, 2H), 3.33 (m, 1H), 3.44 (d, J = 11 Hz, 1H), 3.49 (d, J =
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6 Hz, 2H), 3.64 (m, 1H), 3.75–3.83 (m, 8H), 4.11 (dd, J = 2, 14.5 Hz, 1H), 4.21 (d, J = 5.0 Hz,
1H), 6.29 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m, 7H), 7.41 (d, J = 10.0 Hz, 2H), 7.43 (s, 1H). 13C
NMR (125.6 MHz, CD2Cl2): δ = 12.4, 25.3, 27.3, 25.3, 38.2, 39.4, 49.6, 49.0, 46.3, 48.1, 55.8,
63.9, 68.8, 82.0, 89.3, 94.8, 110.9, 114.8, 126.2, 127.5, 128.2, 129.2, 136.0, 150.8, 158.1, 163.7,
ESI MS (m/z) calculated for C43H61N6O7 [M+H], 772.4; found 772.5.
5’-O-(dimethoxytrityl) 3’-O-(N-Boc-1,3-diamineoethylpropane) thymidine [3.10]: The
starting material 3.5 (200 mg, 0.34 mmol) and N-Boc-1,3-diaminopropane (56.2 mg, 0.32 mmol)
were dissolved in 3 mL of dry THF. The reaction was stirred for 20 min at room temperature and
sodium cyanoborohydride (26 mg, 0.41 mmol, 1.2 equiv) was added to reaction mixture and stirred
for 4 hrs. The reaction was then concentrated in vacuo and purified by flash column
chromatography using EtOAc:Methanol (9:1 v/v) to yield a white foamy product 3.10 in 9% yield.
m.p. 80 °C. [𝛼]23.8
589 : +9.16 (c 0.01, DCM). Rf = 0.10 (EtOAc–Methanol, 9:1 v/v). IR (KBr) υmax
(cm-1) =3514.2, 1791.0, 1771.6, 1721.0, 1710.6, 1635.6, 1608.6, 1557.9, 1540.9, 1511.6, 1422.5,
1365.6, 1222.6, 1177.7, 1092.6, 831.4. 1H NMR (499.79 MHz, CD2Cl2): δ = 1.42 (t, J = 7.0 Hz,
3H), 1.50 (d, J = 12.0 Hz, 3H), 1.57 (s, 1H), 1.74 (m, 2H), 2.33 (d, J = 11.0 2H), 2.38 (m, 3H),
2.46 (t, J = 6.0 Hz, 1H), 2.53 (t, J = 6.0 Hz, 2H), 2.81 (d, J = 8.0 Hz, 1H), 3.18 (m, 2H), 3.33
(m, 1H), 3.49 (d, J = 11 Hz, 2H), 3.64 (m, 1H), 3.76–3.81 (m, 8H), 4.11 (d, J = 2, 14.5 Hz, 1H),
4.21 (dd, J = 5.0 Hz, 1H), 6.29 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m, 7H), 7.19 (d, J = 10.0 Hz,
1H), 11.32 (s, J = 5.0 Hz, 1H) 13C NMR (125.6 MHz, CD2Cl2): δ = 22.2, 25.4, 25.9, 26.3, 29.1,
29.3, 29.3, 29.2, 29.6, 31.9, 53.0, 53.1, 53.4, 53.6, 53.8, 55.2, 55.3, 96.0, 97.3, 99.8, 111.1, 113.2,
128.0, 130.0, 131.0, 135.3, 135.4, 158.9, 195.8. ESI MS (m/z) calculated for C41H52N4O9Na
[M+Na], 767.3; found 767.0.
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5’-hydroxy 3’-O-(methylaminoethyl) thymidine [3.11]: A solution of 3% TCA in DCM (10 mL)
was added dropwise at room temperature to [3.6] (100 mg, 0.166 mmol). The reaction was
continued for 3 hr until complete consumption of starting material was detected by TLC. The crude
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and
lyophilized to dryness. The crude product was purified by silica gel column chromatography
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >99% of a white foamy product [3.11]. m.p. 67 °C.
-1
[𝛼]25
589 +12.65 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm ) =

3734.5, 3710.5, 3633.7, 3180.3, 2597.7, 2260.9, 1688.4, 1843.8, 1754.8, 1406.6, 1228.2, 845.6,
683.9 1H NMR (499.9 MHz, CD2Cl2): δ = 0.82 (t, J = 7.25 Hz, 2H), 1.24 (s, 3H), 1.62 (bs, 1H),
1.80 (s, 3H), 2.23 (d, J = 6.5 Hz, 1H), 2.22-2.25 (m, 1H), 2.52 (s, 2H), 2.70 (d, J = 5.0 Hz, 1H),
2.76 (t, J = 5.25 Hz, 1H), 2.90 (t, J = 7.25 Hz, 1H), 3.60 (s, 1H), 3.70 (s, 1H), 4.0 (m, 1H), 4.10
(d, J = 3.0 Hz, 1H), 6.51 (bs, 1H), 6.14- 6.17 (m, 1H), 7.71 (s, 1H), 11.19 (s, 1H). 13C NMR (126.9
MHz, CD2Cl2): δ = 12.0, 14.7, 22.1, 24.9, 26.8, 28.0, 29.8, 38.6, 52.0, 53.2, 62.0, 64.4, 68.3, 80.0,
80.7, 83.1, 110.0, 136.3, 138.4, 151.0, 164.1, 161.8, 165.2. ESI MS (m/z) calculated for
C13H22N3O5 [M+H], 300.3; found 300.5.
5’-hydroxy 3’-O-(octylaminoethyl) thymidine [3.12]: A solution of 3% TCA in DCM (10 mL)
was added dropwise at room temperature to [3.7] (100 mg, 0.142 mmol). The reaction was
continued for 3 hr until complete consumption of starting material was detected by TLC. The crude
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and
lyophilized to dryness. The crude product was purified by silica gel column chromatography
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >95% of a white foamy product [3.12]. m.p. 70 °C.
-1
[𝛼]22.4
589 +5.5 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm ) =

3433.3, 2252.7, 2126.7, 1843.9, 1792.0, 1771.9, 1733.7, 1658.7, 1642.1, 1401.5, 1027.5, 824.3,
100

762.2. 1H NMR (499.9 MHz, CD2Cl2): δ = 1.10 (d, J = 11 Hz, 2H), 1.26 (s, 16H), 1.61 (bs, 1H),
1.79 (s, 3H), 2.14 (d, J = 6.5 Hz, 1H), 2.22-2.25 (d, J = 7.25 Hz, 1H), 2.52 (s, 1H), 2.69 (d, J =
5.0 Hz, 1H), 2.76 (t, J = 5.25 Hz, 1H), 2.90 (t, J = 4.25 Hz, 2H), 3.60 (s, 1H), 3.70 (s, 1H), 4.2
(bs, 1H), 4.4 (bs, J = 3.0 Hz, 1H), 6.89 (bs, 1H), 6.5 (m, 1H), 7.98 (s, 1H), 11.56 (s, 1H).
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NMR (126.9 MHz, CD2Cl2): δ = 11.9, 12.2, 22.5, 24.2, 25.0, 29.0, 29.1, 31.1, 36.6, 51.0, 52.2,
62.0, 63.4, 80.2, 80.1, 84.1, 84.6, 115.0, 138.9, 151.0, 165.2. ESI MS (m/z) calculated for
C20H36N3O5 [M+H], 398.2; found 398.9.
5’-hydroxy 3’-O-(histaminoethyl) thymidine [3.13]: A solution of 3% TCA in DCM (10 mL)
was added dropwise at room temperature to [3.8] (100 mg, 0.146 mmol). The reaction was
continued for 3 hr until complete consumption of starting material was detected by TLC. The crude
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and
lyophilized to dryness. The crude product was purified by silica gel column chromatography
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >92% of a white foamy product [3.13]. m.p. 75 °C.
-1
[𝛼]22.5
589 +147.4 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm ) =

3523.1, 3500.2, 3129.5, 2900.3, 2692.4, 2529.6, 2319.3, 1843.9, 1754.1, 1631.5, 1348.3, 1254.3,
1083.4, 844.3, 677.9 1H NMR (499.84 MHz, CD2Cl2): δ = 0.99 (s, J = 4.0 Hz, 3H), 1.25 (m, 4H)
,1.53 (d, J = 11 Hz, 3H), 1.59 (s, 1H), 2.24 (m, 1H), 2.46 (t, J = 6.0 Hz, 1H), 2.84 (d, J = 7.9 Hz,
2H), 3.00 (m, 1H), 3.34 (m, 1H), 3.47 (d, J = 11 Hz, 1H), 3.65 (m, 1H), 3.75–3.81 (m, 2H), 4.11
(dd, J = 2, 14.5 Hz, 1H), 4.15 (m, 1H), 6.42 (m, 1H), 6.95 (m, 1H), 7.55(m, 1H), 8.73 (m, 1H),
11.5 (m, 1H). 13C NMR (126.9 MHz CD2Cl2): δ = 11.9, 14.3, 14.4, 22.5, 24.9, 26.8, 29.0, 29.1,
36.6, 52.0, 53.2, 62.0, 64.4, 68.0, 80.2, 80.2, 80.3, 84.2, 84.3, 84.8, 84.9, 85.0, 115.0, 138.4, 151.0,
164.1, 165.2, 200.0, 220.1, 220.8.ESI MS (m/z) calculated for C17H26N5O5 [M+H], 379.1; found
379.0.
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5’ hydroxy 3’-O-(spermineoethyl) thymidine [3.14]: A solution of 3% TCA in DCM (10 mL)
was added dropwise at room temperature to [3.9)] (100 mg, 0.129 mmol). The reaction was
continued for 3 h until complete consumption of starting material was detected by TLC. The crude
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and
lyophilized to dryness. The crude product was purified by silica gel column chromatography
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >99% of a white foamy product. m.p. 79 °C. [𝛼]22.8
589
+29.5 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm-1) = 2836.3,
2730.4, 2450.5, 1744.8, 1631.1, 1335.8, 1249.5, 832.6, 741.6, 675.7. 1H NMR (499.9 MHz,
CD2Cl2): δ = 0.99 (m, 3H), 1.30 (t, J = 10.5 Hz, 3H) , 1.38 (m, 8H), 1.48 (d, J = 10.0 Hz, 3H),
1.57 (s, 1H), 2.23 (m, 2H), 2.46 (t, J = 6.0 Hz, 1H), 2.53 (m, 8H), 2.81 (d, J = 8.0 Hz, 3H), 3.91
(m, 1H), 3.99 (d, J = 11 Hz, 2H), 4.11 (dd, J = 2, 12.5 Hz, 2H), 4.21 (d, J = 5.0 Hz, 2H), 6.28 (m,
1H), 6.95 (m,1H), 11.2 (s, J = 12.5 Hz, 1H), 13C NMR (126.9 MHz, CD2Cl2): δ = 15.4, 60.7, 61.0,
65.9, 65.8, 77.71, 79.6, 81.1, 92.8, 97.7, 107.2, 110.0, 110.9, 112.7, 113.5, 227.3. ESI MS (m/z)
calculated for C22H43N6O5 [M+H], 470.3; found 469.3.
5’-hydroxy 3’-O-(1,3-diamineoethylpropane) thymidine [3.15]: A solution of 90% TFA in
DCM (3 mL) was added dropwise at room temperature to [3.10] (100 mg, 0.134 mmol). The
reaction was continued for 40 min, until complete consumption of starting material was detected
by TLC. The crude product was extracted in DCM/water and the aqueous phase was isolated,
freeze-dried and lyophilized to dryness. The crude product was purified by silica gel column
chromatography (EtOAc:Petroleum ether, 6:4 v/v) to obtain 56% of a white foamy product. m.p.
-1
80 °C. [𝛼]22.6
589 -4.4 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm )
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= 3514.2, 1791.0, 1771.6, 1721.0, 1710.6, 1678.3, 1635.6, 1608.6, 1557.9, 1540.9, 1511.6, 1422.5,
1365.6, 1222.6, 1177.7, 1092.6, 831.4, 766.2, 549.8. 1H NMR (499.9 MHz, CD2Cl2): δ = 1.22 (t,
J = 7 Hz, 2H), 1.24 (s, 4H), 1.60 (bs, 2H), 2.1 (s, 3H), 2.14 (d, J = 12.5 Hz, 1H), 2.82 (s, 3H),
3.50 (s, 1H), 3.71 (s, 1H), 4.25 (m, 6H), 4.20 (d, J = 4.0 Hz, 1H), 5.98 (t, J = 12.5 Hz, 1H), 10.0
(s, 1H), 11.6 (s, 1H). 13C NMR (126.9 MHz, CD2Cl2): δ = 13.1, 13.2, 22.5, 24.2, 26.9, 29.0, 29.3,
30.9, 36.6, 52.1, 53.2, 62.0, 65.0, 80.0, 80.5, 84.2, 84.3, 84.8, 84.9, 99.2, 100.0, 110.0, 138.3,
145.4, 162.0, 198.1, 206.2, 208.9, 210.7. ESI MS (m/z) calculated for C15H27N4O5 [M+H], 343.1;
found 343.2.
5’-carboxy 3’-O-(methylaminoethyl) thymidine [3.16]: To a solution of [3.11] (500 mg, 1.67
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (45.4 mg,
0.241 mmol), and iodobenzene diacetate (BAIB) (682 mg, 2.29 mmol) at room temperature. After
the mixture was stirred for 2 h, MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction mixture
and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase was
isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash
chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in 62%
yield. M.p= 79°C. [𝛼]22.6
589 = 143.5 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr)
υmax (cm-1)= 2951.0, 2586.9, 1868.5, 1843.9, 1754.1, 1643.0, 1471.3, 1368.0, 1343.1, 1252.1,
1117.6, 839.9, 743.7, 679.1. 1H NMR (499.9 MHz, DMSO): δ= 1.19 (t, J = 14.0 Hz, 3H), 1.56 (t,
J = 4 Hz, 3H), 2.70-2.81 (m, 7H), 3.30-3.35 (m, 1H), 3.52 (bs, 1H), 3.98-4.05 (m, 2H), 4.42-4.47
(m, 1H), 4.49 (d, J = 2 Hz, 1H), 6.23 (m, 1H), 9.10 (s, 1H), 11.24 (bs, 1H). 13C NMR (129.69
MHz, DMSO-d6): δ= 11.0, 12.3, 21.5, 39.7, 56.7, 60.1, 62.3, 74.6, 80.1, 82.6, 83.9, 110.1, 113.6,
116.8, 128.8, 129.7, 136.7, 144.1, 150.2, 159.8, 162.6, 170.1, 201.9. ESI MS (m/z) calculated for
C13H19N3O6 [M+], 313.1; found 313.0.
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5’-carboxy 3’-O-(octylaminoethyl) thymidine [3.17]: To a solution of [3.12] (500 mg, 1.26
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (36.2 mg,
0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.30 mmol) at room temperature. After
the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction
mixture and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase
was isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash
chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in 29%
yield. M.p= 82°C. [𝛼]22.6
589 = -8.25 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr)
υmax (cm-1)= 2934.3, 1791.6, 1658.7, 1456.3, 1364.5, 1270.7, 1133.2, 894.9, 825.1, 733.7, 669.1.
1

H NMR (499.9 MHz, DMSO): δ= 1.20 (t, J = 11.0 Hz, 1H), 1.60 (m, 17H), 2.40-2.56 (m, 4H),

2.60-2.90 (m, 3H), 3.28-3.59 (m, 1H), 3.63 (d, J = 12 Hz, 1H), 4.01-4.05 (m, 2H), 4.44-4.45 (m,
1H), 6.23 (s, 1H), 6.82 (s, 1H), 9.37 (s, 1H), 11.25 (bs, 1H). 13C NMR (125.69 MHz, DMSO-d6):
δ= 13.2, 39.5, 39.6, 58.2, 62.1, 64.8, 80.2, 83.2, 84.4, 109.0, 112.8, 115.6, 117.8, 131.8, 134.8,
139.0, 142.6, 162.8, 171.4, 179.9, 175.8, 194.2, 198.2, 204.8. ESI MS (m/z) calculated for
C14H33N3O6 [M+], 411.2; found 411.9.
5’-carboxy 3’-O-(histamineoethyl) thymidine [3.18]: To a solution of [3.13] (500 mg, 1.32
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (36.2 mg,
0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.298 mmol) at room temperature. After
the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction
mixture and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase
was isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash
chromatography (CHCl3:MeOH 9:1 v/v) in >99% yield. M.p= 85°C. [𝛼]22.6
589 = -7.69 (c 0.01,
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DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr) υmax (cm-1)= 2950.5, 1843.9, 1758.3, 1665.3,
1471.5, 1388.3, 1339.4, 1230.7, 1118.7, 1014.6, 835.9, 737.4, 676.3. 1H NMR (499.84 MHz,
DMSO- d6): δ = 0.89 (t, J = 4.0 Hz, 1H), 1.25 (m, 3H) , 1.60 (s, 1H), 2.22 (m, 1H), 2.83 (d, J = 5
Hz, 2H), 3.02 (m, 1H), 3.34 (m, 1H), 3.72 (m, 7H), 4.14 (dd, J = 14.5 Hz, 1H), 4.19 (m, 1H),
6.15 (m, 1H), 7.25(m, 1H), 9.0 (s, 1H), 11.18 (bs, 1H). 13C NMR (125.69 MHz, DMSO-d6): δ=
10.9, 37.3, 54.6, 63.9, 69.7, 79.0, 83.7, 84.4, 86.6, 110.2, 113.2, 116.1, 126.9, 127.9, 128.2, 130.1,
135.0, 135.5, 135.7, 135.8, 145.0, 150.4, 151.7, 158.9, 163.4, 179.2, 204.8. ESI MS (m/z)
calculated for C17H23N5O6 [M-H], 393.4; found 392.1.
5’-carboxy 3’-O-(spermineoethyl) thymidine [3.19]: To a solution of [3.14] (500 mg, 1.06
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (36.2 mg,
0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.23 mmol) at room temperature. After
the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction
mixture and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase
was isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash
chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in 92%
yield. M.p= 89°C. [𝛼]25
589 = +63.25 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr)
υmax (cm-1)= 2949.0, 1868.5, 1843.9, 1665.7, 1472.0, 1366.5, 1332.4, 1231.5, 1118.7, 1089.1,
1059.2, 1014.5, 975.8, 635.8, 734.7, 678.1. 1H NMR (499.8 MHz, DMSO-d6): δ = 0.98 (m, 1H),
1.30 (t, J = 10.5 Hz, 2H) , 1.38 (m, 4H), 1.48 (d, J = 10.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H),
2.46 (t, J = 6.0 Hz, 1H), 2.53 (m, 7H), 2.81 (d, J = 8.0 Hz, 1H), 3.91 (m, 4H), 3.99 (d, J = 11 Hz,
3H), 4.11 (dd, J = 12.5 Hz, 4H), 4.21 (d, J = 5.0 Hz, 2H), 6.28 (m, 1H), 6.95 (m,3H), 11.2 (s, J =
12.5 Hz, 1H), 13.0 (m, 1H). 13C NMR (125.70 MHz, DMSO-d6): δ= 12.1, 14.5, 21.2, 55.5, 60.2,
64.2, 74.7, 80.4, 83.3, 84.1, 84.2, 86.5, 110.2, 113.75, 128.1, 128.4, 130.2, 135.6, 135,8, 136.0,
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145.1, 150.8, 158.6, 164.1, 170.8, 201.1ESI MS (m/z) calculated for C22H40N6O6 [M-H], 484.3;
found 483.3.
5’-carboxy 3’-O-(1,3-diamineoethylpropane) thymidine [3.20]: To a solution of [3.15] (500
mg, 1.46 mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO)
(36.2 mg, 0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.298 mmol) at room
temperature. After the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was
added to the reaction mixture and stirred for 24 h. The crude product was extracted in DCM/water
and the aqueous phase was isolated, freeze-dried and lyophilized to dryness. The crude product
was purified by flash chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as
white powder in 90% yield. M.p= 80°C. [𝛼]22.8
589 = -4.4 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH
9:1 v/v). IR (KBr) υmax (cm-1)= 2933.9, 1678.2, 1365.8, 1179.3, 1131.2 1H NMR (499.9 MHz,
DMSO-d6): δ = 1.25 (t, J = 11.5 Hz, 1H), 1.24-1.59 (m, 8H), 2.15 (s, 3H), 2.19 (d, J = 6 Hz, 1H),
2.80 (bs, 2H), 3.51 (s, 2H), 3.70 (s, 1H), 4.15-4.20 (m, 1H), 4.42 (bs, 2H), 6.0 (t, J = 8 Hz, 1H),
11.62 (s, 1H), 13.25 (bs, 1H). 13C NMR (125.70 MHz, DMSO-d6): δ= 12.9, 14.3, 22.5, 26.2, 26.6,
29.1, 29.5, 31.7, 83.2, 84.4, 85.9, 108.9, 108.9, 138.6, 150.9, 164.4, 173.4. ESI MS (m/z)
calculated for C15H24N4O6Na [M+Na], 379.1; found 379.0.
Solid phase bioconjugation.
Solid-phase bioconjugation of peptide nucleolipids (3.22-3.31) were performed on an oil
bath reaction apparatus with a stirring block. The peptide-bound Rink amide poly (ethylene glycol)
resin (Nova PEG, 0.47 mmol/g) 3.21, was added into a microglass tube and slowly agitated with
DMF (500 µL) at 60 ºC. Nucleolipids (3.16-3.20, 3 eq.) were added in DMF (500 µL) along with
NMM (6 eq.) and HCTU (3 eq.). The reaction mixture was preactivated for 7 min before being
slowly added to the resin-bound peptide and agitated for 14 h at 60 ºC. Following coupling, the
106

resin was washed with MeOH, DMF and DCM (3x15 mL) followed by deprotection of the Fmoc
protecting group (30 min) with 20% piperidine in DMF. The resin was then washed (MeOH, DMF
and DCM) and dried with N2(g). Labeling of the Ahx-peptide N-terminus with fluorescein
isothiocyanate (FITC, 1.1 eq.) in pyridine:DMF:DCM (12:7:5 v/v/v) was accomplished in the
dark, overnight at room temperature. Following synthesis, peptide cleavage from the solid support
and deprotection of the side-chain protecting groups were accomplished with concentrated
trifluoroacetic acid (TFA, 95%) with minimal addition (5%) of reaction scavengers (i.e. H2O,
triethylsilane). The cleavage and deprotection reaction was completed in 2 hrs at room
temperature. Peptide-nucleolipid samples (3.22-3.31) were concentrated, precipitated in cold
ether, and isolated as white pellets for LC/MS analyses and purification.
Characterization of peptides by LC/MS:
Crude peptide-nucleolipid samples were dissolved in MeOH/H2O for LCMS analyses.
Sample analyses were performed on an Agilent 1100 series ESI-LCMS with single quadrupole
mass analyzer and LC conditions which used a linear binary gradient (2-80% MeOH/H2O, 0.1%
FA, over 25min). Analytical RP-HPLC was performed using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) using a linear binary gradient, 20-80% or 2-82%
MeCN/H2O, 0.1%FA, over 17 min at 25°C, with a 1 mL/min flow rate and detection at 220 nm
and 260 nm. Samples collected after purification were lyophilized to a white solid and re-dissolved
in 50:50 v/v H2O:MeOH to confirm purity and identity by LCMS analyses.
Circular Dichroism (CD) Spectroscopy:
Samples were prepared 12-16 hr. ahead of time in H2O:TFE (50:50, v/v) and stored at 5
ºC. CD spectra were collected as an average of 3 scans on an Olis Circular Dichroism (CD)
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Spectrophotometer (Model: 24994 Rapid Scanning Monochromator, online instrument system)
from 260-190 nm, using 1 nm bandwidth and 0.5 min step size at 25 oC. Samples were blank
corrected, the data was smoothed and converted to molar ellipticity values from the equation [θ] =
θ /cl, where θ is the molar ellipticity (mdeg), c is the molar concentration of the peptides (12.5
µM) and l is the path length of the cell (1 cm). The data was imported into Microsoft Excel and
the CD spectra were plotted in terms of molar ellipticity vs wavelength.
UV/Vis Spectroscopy.
The final concentrations of the peptide solutions was determined by UV/Vis
spectrophotometry at 214 nm ( value of peptides and calculated from the equation:
214 = (peptidebond)(npeptidebonds) + Σ (aminoacid(i))(naminoacid(i)).
The analyses were conducted on an 8452A Diode Array Spectrophotometer from OLIS, with
wavelength range set from 190 – 600 nm with maximum absorption collected at 220 and 260 nm
in addition to 490 nm for the FITC-labeled peptides. Peptide concentrations were standardized at
12.5 M.
Cell Viability.
To evaluate the MM1S cells’ viability following treatment with the synthetic peptide-nucleolipid
bioconjugates, 3.22-3.31, the MM1S cells were incubated for 24 h in a 24 well plate, at 50,000
viable cells/well. MM1S cells were left untreated, and treated with the synthetic peptidenucleolipid bioconjugates, 3.22-3.31, (2.5 M) at 37°C in 5% CO2 humidified air. Cells were then
collected and washed with FACS buffer, centrifuged, and suspended in Guava Nexin Reagent®
(100 L/tube, from EMD Millipore). Following incubation (20 min) at room temperature in the
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dark, the MM1S cells were analyzed for early and late apoptotic events by flow cytometry
following the vendor instructions.
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CHAPTER 4. CONCLUSIONS, FUTURE WORK AND CONTRIBUTIONS TO
KNOWLEDGE
4.1 CONCLUSIONS MADE IN THIS THESIS
4.1.1 SYNTHESIS, CHARACTERIZATION AND ANTI-CANCER ACTIVITY OF A
PEPTIDE-NUCLEOLIPID BIOCONJUGATE
In Chapter 2, the design, synthesis and characterization of a new class of “killer” peptide
nucleolipid bioconjugate was described for anti-cancer applications. These research objectives
were accomplished by developing a solution-phase synthesis strategy for making the requisite 5’carboxy 3’-hexadecylamine thymidine nucleolipid (Scheme 2.1). The key step in this synthetic
approach was based on a reductive amination reaction which condensed hexadecylamine onto the
3’-aldehyde-derived thymidine building block. This strategy was envisioned as an entry point for
coupling a variety of alkyl, aryl and heterocyclic amines in order to generate functionally diverse
nucleolipids. In this proof-of-concept study, the 3’-hexadecylamine-derived nucleolipid was
synthesized in good yields and converted to the 5’-carboxy-derived nucleolipid following 5detritylation and oxidation reactions. The final nucleolipid product was characterization by NMR,
IR spectroscopy and mass spectrometry in order to validate identity and compound purity.
This thymidine-derived nucleolipid was rationally designed and developed for conjugation
with the pro-apoptotic peptide D-(KLAKLAK)2 sequence (Figure 2.1). This so-called “killer”
peptide has shown the ability to induce bacterial cell death, with limited toxicity observed in
mammalian cells [1]. In order to improve the cytotoxic activity of the D-(KLAKLAK)2 sequence
towards malignant mammalian cell types, such as cancer, the amphiphilic nucleolipid was
anticipated to enhance cell permeability and mitochondria localization of the D-(KLAKLAK)2AK sequence for potentiating its anti-cancer activity. The native D-(KLAKLAK)2-AK and
palmitamide derived sequences were made as controls using solid phase peptide synthesis. In the
case of the palmitamide-derived sequence, an orthogonally protected Lys(Dde) was unmasked
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using buffered hydroxylamine and the liberated -amino group was reacted with palmitic acid
using HCTU coupling conditions to afford the C-terminal palmitamide derived D-(KLAKLAK)2AK. The HCTU-based coupling conditions were also used to generate the nucleolipid derived D(KLAKLAK)2-AK sequence. These sequences also contained N-terminal modifications, including
the incorporation of the Ahx linker and FITC. The peptide bioconjugates were isolated in sufficient
yields (10-33%) and purities (≥96%) for structure-activity relationship studies.
Comparison of retention times of the peptide conjugates with the native sequence indicated
that conjugation of the D-(KLAKLAK)2-AK sequence with palmitic acid and nucleolipid
produced more hydrophobic, retained sequences on the C18 reverse-phase HPLC column (Figure
2.2. B). Moreover, UV-Vis absorption studies validated the characteristics absorptions for the
peptide (220 nm) and nucleolipid (260 nm) (Figure 2.2 C). CD spectroscopy was used to study
the secondary structures of the conjugates in comparison to the native sequence. Distinct α-helical
secondary structures were observed for all samples in a H2O:TFE solvent system indicating that
conjugation retains the helical peptide character of the sequence (Figure 2.2D and Table 2.2).
DLS and TEM studies were used to confirm the self-assembly of the peptide high-ordered
nanostructures, presumably due to the amphiphilic nature of the sequence (Figure 2.3). Thus, the
amphiphilic peptide bioconjugates were found to retain the structure (-helix) characteristics of
the native sequences, while fine-tuning its polar properties for biological action in malignant
cancer cells. We hypothesized that the positively charged, amphiphilic -helical peptide
conjugates would display enhanced cell permeability and mitochondria localization leading to
toxicity in cancer cells. In order to test this hypothesis, the anti-cancer activity of the peptide
conjugates were examined relative to the native sequence.
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A 60 cancer cell line screen was performed at the National Cancer Institute, testing the
anti-proliferative properties of the peptides dosed at a single concentration. In this screen, the
amphiphilic peptide bioconjugates were found to be more active than the native D-(KLAKLAK)2AK sequence, especially in a selected panel of non-small cell lung carcinoma (Table 2.3, Figures
2.4-2.7). The A549 lung cancer cell line was found to be the most sensitive, with the nucleolipidderived sequence exhibiting the greatest cytotoxicity followed by the palmitamide and the native
peptide sequence. Thus, conjugation of the D-(KLAKLAK)2-AK sequence with the amphiphilic
nucleolipid has served to potentiate the anti-cancer activity of the so-called “killer” peptide
sequence [2]. A structure-activity relationship study was developed in Chapter 3 in order to explore
the influence of nucleolipid modifications on the anti-cancer activity of the D-(KLAKLAK)2-AK
sequence.

4.1.2

DIVERSITY

ORIENTED

SYNTHESIS

OF

PEPTIDE

NUCLEOLIPID

BIOCONJUGATES FOR STRUCTURE-ACTIVITY RELATIONSHIP STUDIES
In Chapter 3, a new diversity oriented synthesis approach is described for the generation
of modified nucleolipids and their incorporation within the native D-(KLAKAK)2-AK sequence.
These methods are important for the generation of new peptide nucleolipid bioconjugates that may
serve as bifunctional probes for exploring the influence of nucleolipid modification on the anticancer activity of the D-(KLAKAK)2-AK sequence. The diversity oriented synthesis approach
described in chapter 3 is based on our existing reductive amination methodology [2]. Extension of
the substrate scope related to this method allowed for the condensation of alkylamines,
polyamines, and heterocyclic amines onto the 3’-aldehyde derived thymidine precursor (Figure
3.5). This two-step one pot reaction allowed for the generation of structurally diverse nucleolipids
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which were subsequently converted into their reactive 5’-carboxy derived nucleolipids following
our previously described detritylation and oxidation conditions [2]. Each nucleolipid was
characterized by a combination of 1H, 13C NMR, IR spectroscopy and mass spectrometry in order
to confirm identities and purities. The isolated 5’-carboxy derived nucleolipids were incorporated
at the Lys C-terminus of the D-(KLAKAK)2-AK sequence by the HCTU-mediated coupling
conditions previously described [2]. Furthermore, peptides were generated with and without the
N-terminal FITC for exploring structure-activity relationships against cellular tumor targets
(Figure 3.6).
The isolated peptide-nucleolipid bioconjugates were analyzed and purified by RP HPLC.
The identities of the pure bioconjugates were confirmed by LC-MS for exploring our structureactivity relationship studies. The amphiphilic properties of the peptide-nucleolipid bioconjugates
were initially explored by RP-HPLC (Figure 3.7). In this study, the alkylamine and polyamine
derived nucleolipids were found to impart greater hydrophobicity onto the D-(KLAKAK)2-AK
sequence when compared to the histamine-derived nucleolipids. CD spectroscopy was then used
to evaluate the secondary structures (if any) of the peptides in H2O:TFE. The combination of
H2O:TFE served to mimic the amphiphilic lipid bilayer microenvironment that may stabilize
peptide secondary structures. The structurally diverse nucleolipids were found to retain -helical
peptide secondary structures, albeit, with varying effects on (Percentage of) helical character
(Figure 3.9).
The biological evaluation of the small library of peptide nucleolipid bioconjugates has been
tested on the HepG2 hepatoblastoma cell culture. In this assay, a Guava Nexin® Reagent (EMD
Millipore) was used to assess early and late-stage apoptosis by flow cytometry [3]. The results
revealed no signifncant populations in early and late stage apoptotic events for the HepG2 cells
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when treated with the synthetic bioconjugates, (Figure 3.10). These results are preliminary and
additional biological testing is anticipated to confirm the capabilities of structurally diverse
nucleolipids to potentiate the cancer cell death effects of the D-(KLAKAK)2-AK sequence.
Furthermore, the FITC-labeled bioconjugates may provide important mechanistic information
related to cell permeability and mitochondrial localization for anti-cancer activity. In a related
study, the lead nucleolipid-derived D-(KLAKAK)2-AK sequence may be extended with cancertargeting peptide sequences in order to facilitate selective anti-cancer activity. The latter is a
current focus of our on-going research work for generating potent and selective anti-cancer
peptides.
4.2 PRELIMINARY STUDIES AND FUTURE WORK TOWARDS THE DEVELOPMENT
OF A CANCER-TARGETING PEPTIDE-NUCLEOLIPID BIOCONJUGATE
4.2.1 RATIONAL DESIGN
The Pep42 cancer-targeting peptide has been a cornerstone sequence in our research group
for the development of selective anti-cancer approaches [4]. Pep42, was selected by Janda and coworkers as a short, cyclic peptide sequence capable of binding to and internalizing within cancer
cells that express GRP78 on the cell surface [5]. Considering that GRP78 functions as an
oncoprotein signaling tumor initiation, proliferation, invasion and drug resistance, it has been
classified as a therapeutically relevant biomarker in cancer [6]. Furthermore, GRP78 is
overexpressed on the cell surface of many transformed primary tumors, but not on normal, healthy
cells making the identification of cell surface GRP78 ligands of critical importance for the
development of cancer-targeting strategies. In our approach, a lead nucleolipid-derived D(KLAKAK)2-AK sequence is extended at the N-terminus with the Pep42 sequence,
CTVALPGGYVRVC,, followed by the incorporation of the aminohexanoic acid linker (AHx) and
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fluorescein isothiocyanate (FITC). Additionally, poly(ethylene) glycol spacers (0, 3, 6, 12) may
be introduced in between the Pep42 and D-(KLAKAK)2 sequence to provide spatial control in
between the bifunctional peptide sequences and to also help promote aqueous solubility and
biocompatibility. A structure representation of a first generation FITC-Ahx-Pep42-D(KLAKAK)2-AK-nucleolipid conjugate is described in Figure 4.1.

Figure 4.1. Rational design of the GRP78-targeting FITC-Ahx-Pep42-D-(KLAKAK)2-AKnucleolipid conjugate.

4.2.2. SYNTHESIS
Working alongside Adah Beck, a first year undergraduate student working in the laboratory
of Dr. David Sabatino in the Department of Chemistry and Biochemsitry, a synthesis strategy for
the desired bioconjugate was designed and developed. Fmoc-based solid phase peptide synthesis
was used for the preparation of the GRP78-targeting FITC-Ahx-Pep42-D-(KLAKAK)2-AKnucleolipid conjugate. The peptide sequence was generated on a Rink Amide NovaPEG resin. At
the C-terminus, the Lys(Dde) residue was incorporated and selectively deprotected on solid phase
for the coupling of the carboxy-derived nucleolipid. HCTU-coupling conditions were once again
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used to effectively couple the nucleolipd and the Fmoc-amino acids on solid phase. The first
representative example of the Pep42- D-(KLAKAK)2-AK-nucleolipid conjugate was synthesized
without a PEG spacer, however, the Ahx linker was incorporated at the N-terminus for FITC
incorporation. In this final synthetic step, a portion of the peptide bound support was cleaved and
deprotected without the FITC label, whereas, another portion of the resin was used to couple FITC
at the N-terminus. Following cleavage and deprotection, the crude peptide bioconjugates were
analyzed by LCMS to confirm identities and purities. Our synthetic strategy for making the
GRP78-targeting FITC-Ahx-Pep42-D-(KLAKAK)2-AK-nucleolipid conjugate proved fruitful
(Scheme 4.1 and Figures 4.2, 4.3) and sets the stage for making a small library of Pep42- D(KLAKAK)2-AK-nucleolipid bioconjugates for exploring selective and potent anti-cancer
activities in tumors that overexpress GRP78 at the cell surface. The latter is a focal point of our
current studies aimed towards the development of potent GRP78-targeting ligands.

Scheme 4.1.

Fmoc-solid phase peptide synthesis of Pep42-D-(KLAKAK)2-AK-nucleolipid

bioconjugates.
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Figure 4.2. LC-MS analysis of crude AHx-CTVALPGGYVRVC-D-(KLAKLAKKLAKLAK)AK-Dde using a linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695
Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow
rate of 1.0 mL/min with detection at 220 nm.
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Figure 4.3. ESI-MS analysis of crude AHx-CTVALPGGYVRVC-D-(KLAKLAKKLAKLAK)AK-Dde using a linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695
Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow
rate of 1.0 mL/min with detection at 220 nm.
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Figure A5.

LCMS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AKOctylamine nucleolipid, 3.23
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Figure A6.

ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AKOctylamine nucleolipid, 3.23
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Figure A7.

RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AKHistamine nucleolipid, 3.24
135

Figure A8.

LCMS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine
nucleolipid, 3.24
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Figure A9.

ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AKHistamine nucleolipid, 3.24
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Figure A10.

RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AKSpermine nucleolipid, 3.25
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Figure A11.

LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AKSpermine nucleolipid, 3.25
139

Figure A12.

ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AKSpermine nucleolipid, 3.25
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Figure A13.

RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.26
141

Figure A14.

LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.26
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Figure A15.

ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK1,3-diaminopropane nucleolipid, 3.26
143

Figure A16.

RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Methylamine nucleolipid, 3.27
144
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Figure A17.

LCMS analysis of crude FITC-AHx-D-(KLAKLAKKLAKLAK)-AKMethylamine nucleolipid, 3.27
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Figure A18.

ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Methylamine nucleolipid, 3.27
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Figure A19.

RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Octylamine nucleolipid, 3.28
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Figure A20.

LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKOctylamine nucleolipid, 3.28
148

Figure A21.

ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Octylamine nucleolipid, 3.28
149

Figure A22.

RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Histamine nucleolipid, 3.29
150

Figure A23.

LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKHistamine nucleolipid, 3.29
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Figure A24.

ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Histamine nucleolipid, 3.29
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Figure A25.

RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Spermine nucleolipid, 3.30
153

Figure A26.

LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKSpermine nucleolipid, 3.30
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Figure A27.

ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-Spermine nucleolipid, 3.30
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Figure A28.

RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)AK-1,3-diaminopropane nucleolipid, 3.31
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Figure A29.

LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK1,3-diaminopropane nucleolipid, 3.31
157

Figure A30.

LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK1,3-diaminopropane nucleolipid, 3.31
158

Figure A31.
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Figure A32.

13

C NMR spectrum of 2.2
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Figure A33.

1

H NMR spectrum of 2.3
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Figure A34.

13

C NMR spectrum of 2.3
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Figure A35.

1

H NMR spectrum of 2.4
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H NMR spectrum of 2.2
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Figure A36.

13

Figure A37.

1

Figure A38.

13

Figure A39.
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Figure A40.

13

C NMR spectrum of 2.4
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H NMR spectrum of 2.5
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C NMR spectrum of 2.5
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H NMR spectrum of 2.6
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C NMR spectrum of 2.6
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Figure A41.

ESI-MS of D-(KLAKLAKKLAKLAK)
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Figure A42.

ESI-MS of D-(KLAKLAKKLAKLAK)-AK
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Figure A43.

ESI-MS of D-(KLAKLAKKLAKLAK)-AK-Palmitamide
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Figure A44.

ESI-MS of D-(KLAKLAKKLAKLAK)-AK-Nucleolipid
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Figure A45.

ESI-MS of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AK
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Figure A46.

ESI-MS of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AKPalmitamide

Figure A47.
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ESI-MS of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AKHexadecyl Nucleolipid
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Figure A48.

RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK)
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Figure A49.

RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK) using a linear
gradient 2-83% MeCN/H2O (0.1% FA)

Figure A50.

RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK)-AK using a
linear gradient 2-80% MeOH/H2O (0.1% FA)

Figure A51.

177

RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK
using a linear gradient 2-80% MeCN/H2O (0.1% FA)

Figure A54.
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RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK
using a linear gradient 2-80% MeOH/H2O (0.1% FA)

Figure A53.
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RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK)-AK using a
linear gradient 2-80% MeCN/H2O (0.1% FA)

Figure A52.
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RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AKHexadecylamine nucleolipid using a linear gradient 2-80% MeOH/H2O
(0.1% FA)
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Figure A55.

RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AKhexadecylamine nucleolipid using a linear gradient 2-80% MeCN/H2O
(0.1% FA)

Figure A56.

180

RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AKhexadecylamine nucleolipid using a linear gradient 2-80% MeOH/H2O
(0.1% FA)

Figure A57.
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RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AKhexadecylamine nucleolipid using a linear gradient 2-80% MeCN/H2O
(0.1% FA)

Figure A58.
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RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AKPalmitamide using a linear gradient 20-80% MeCN/H2O (0.1% FA)183

Figure A59.

RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AKPalmitamide using a linear gradient 20-80% MeOH/H2O (0.1% FA)184

Figure A60.

RP-HPLC analysis of purified FITC-D-(KLAKLAK)2-AK-Palmitamide
using a linear gradient 20-80% MeOH/H2O (0.1% FA)

Figure A61.
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RP-HPLC analysis of purified FITC-D-(KLAKLAK)2-AK-Palmitamide
using a linear gradient 20-80% MeCN/H2O (0.1% FA)
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Figure A62.
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Figure A63.

13

C NMR spectrum of 3.6
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Figure A64.

1

H NMR spectrum of 3.7
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Figure A65.

13

C NMR spectrum of 3.7
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Figure A66.

1

H NMR spectrum of 3.8
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Figure A67.

13

C NMR spectrum of 3.8
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Figure A68.

1

H NMR spectrum of 3.9
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Figure A69.

13

C NMR spectrum of 3.9
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Figure A70.

1

H NMR spectrum of 3.10
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Figure A71.

13

C NMR spectrum of 3.10
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Figure A72.

1

H NMR spectrum of 3.11
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H NMR spectrum of 3.6
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Figure A73.

13

C NMR spectrum of 3.11
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Figure A74.

1

H NMR spectrum of 3.12
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Figure A75.

13

C NMR spectrum of 3.12
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Figure A76.

1

H NMR spectrum of 3.13
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Figure A77.

13

C NMR spectrum of 3.13
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Figure A78.

1

H NMR spectrum of 3.14
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Figure A79.

13

C NMR spectrum of 3.14
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Figure A80.

1

H NMR spectrum of 3.15
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Figure A81.

13

C NMR spectrum of 3.15
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Figure A82.

1

H NMR spectrum of 3.16
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Figure A83.

13

C NMR spectrum of 3.16
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Figure A84.

1

H NMR spectrum of 3.17
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Figure A85.

13

C NMR spectrum of 3.17
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Figure A86.

1

H NMR spectrum of 3.18
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Figure A87.

13

C NMR spectrum of 3.18
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Figure A88.
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H NMR spectrum of 3.19
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Figure A89.
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C NMR spectrum of 3.19
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Figure A90.
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H NMR spectrum of 3.20

215

Figure A91.
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C NMR spectrum of 3.20
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216

Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine nucleolipid, 3.22
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220nm

Results and analysis:
Retention Time
1
2

10.671
11.608

Area
395043
71105

% Area
98.95
1.05

Height
133547
4450

Figure A1. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine
nucleolipid, 3.22 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.

130

Figure A2. LC-MS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine
nucleolipid, 3.22 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A3. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine
nucleolipid, 3.22 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine nucleolipid, 3.23
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220nm

Results and analysis:
Retention Time
1
2

10.262
11.262

Area
1797
108567

% Area
4.05
95.95

Height
23666
33003

Figure A4. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine
nucleolipid, 3.23 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A5. LCMS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AK-Octcylamine
nucleolipid, 3.23 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A6. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine
nucleolipid, 3.23 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine nucleolipid, 3.24
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220nm

Results and analysis:
Retention Time
1
2
3

8.998
9.304
10.684

Area
31396
573102
188451

% Area
1.34
95.01
3.65

Height
30778
123665
161128

Figure A7. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine
nucleolipid, 3.24 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A8. LCMS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine
nucleolipid, 3.24 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.

137

Figure A9. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine
nucleolipid, 3.24 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine nucleolipid, 3.25
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220nm

Results and analysis:
Retention Time
1
2
3

9.473
10.826
12.035

Area
318468
763932
1193838

% Area
1.20
2.46
96.34

Height
1141
53514
95167

Figure A10. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine
nucleolipid, 3.25 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A11. LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine
nucleolipid, 3.25 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A12. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine
nucleolipid, 3.25 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-diaminopropane nucleolipid, 3.26
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220nm

Results and analysis:
Retention Time
1
2
3
4

8.749
10.176
10.707
11.948

Area
38426
586519
296971
857782

% Area
0.86
1.20
0.91
97.03

Height
86646
79560
36979
97567

Figure A13. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.26 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A14. LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.26 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A15. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.26 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine, 3.27
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 495nm

Results and analysis:
Retention Time
1

13.290

Area
32452

% Area
100

Height
1232

Figure A16. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKMethylamine nucleolipid, 3.27 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 495 nm.
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Figure A17. LCMS analysis of crude FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine
nucleolipid, 3.27 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 495 nm.

146

Figure A18. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKMethylamine nucleolipid, 3.27 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 495 nm.
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine, 3.28
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220 nm

Results and analysis:
Retention Time
1

15.047

Area
108239

% Area
100

Height
9432

Figure A19. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKOctylamine nucleolipid, 3.28 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A20. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine
nucleolipid, 3.28 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A21. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKOctylamine nucleolipid, 3.28 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine, 3.29
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220 nm

Results and analysis:
Retention Time
1
2

12.167
12.573

Area
108239
199388

% Area
50.0
49.5

Height
2873
3127

Figure A22. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKHistamine nucleolipid, 3.29 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A23. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine
nucleolipid, 3.29 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A24. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKHistamine nucleolipid, 3.29 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine, 3.30
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220 nm

Results and analysis:
Retention Time
1
2

13.326
13.331

Area
8348
121470

% Area
1.4
98.6

Height
454
946

Figure A25. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKSpermine nucleolipid, 3.30 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A26. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine
nucleolipid, 3.30 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at
a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A27. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AKSpermine nucleolipid, 3.30 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-diaminopropane, 3.31
Solvent: 2-80% MeOH (0.1% FA) over 17 min
Detection: PDA 220 nm

Results and analysis:
Retention Time
1

Area

15.036

% Area
100

140525

Height
8938

Figure A28. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.31 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.

157

Figure A29. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.31 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A30. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3diaminopropane nucleolipid, 3.31 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Figure A31. 1H NMR spectrum of 2.2
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2.2

Figure A32. 13C NMR spectrum of 2.2

161

2.3

Figure A33. 1HNMR spectrum of 2.3
162

2.3

Figure A34. 13CNMR spectrum of 2.3
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Figure A35. 1H-NMR spectrum of 2.4
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2.4

Figure A36. 13C-NMR spectrum of 2.4
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Figure A37. 1H-NMR spectrum of 2.5
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Figure A38. 13C-NMR spectrum of 2.5
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Figure A39. 1H-NMR spectrum of 2.6
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Figure A40. 13C-NMR spectrum of 2.6
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Figure A41. ESI-MS spectra of D-(KLAKLAKKLAKLAK)
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Figure A42. ESI-MS spectra of D-(KLAKLAKKLAKLAK)-AK
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Figure A43. ESI-MS spectra of D-(KLAKLAKKLAKLAK)-AK-Palmitamide
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Figure A44. ESI-MS spectra of D-(KLAKLAKKLAKLAK)-AK-Nucleolipid
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Figure A45. ESI-MS spectra of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AK
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Figure A46. ESI-MS spectra of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AK-Palmitamide.

Figure A47. ESI-MS spectra of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AK-Hexadecyl
Nucleolipid
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m /z

Sequence: Purified Crude D-(KLAKLAKKLAKLAK)
Solvent: 2-83% MeCN (0.1% TFA) over 18 min
6.987

Detection: PDA 220nm
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Results and analysis:
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Area
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% Area
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Height
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Figure A48. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK) using a linear gradient
2-83% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 column (3.9 x
150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with
detection at 220 nm.
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Figure A49. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK) using a linear gradient
2-83% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 column (3.9 x
150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with
detection at 220 nm.
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Sequence: NH2-AHx-D-(KLAKLAK)2-AK
Solvent: 2to80MeOH (0.1%FA) over 17 min
Detection: PDA 220nm
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Figure A50. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK)-AK using a linear
gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.
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Sequence: NH2-AHx-D-(KLAKLAK)2-AK
Solvent: 2-80% MeCN (0.1% FA) over 17 min
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Figure A51. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK)-AK using a linear
gradient 2-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.
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Sequence: FITC-NH2-AHx-D-(KLAKLAK)2-AK
Solvent: 2to80MeOH (0.1%FA) over 17 min
Detection: PDA 220nm
0.50

10.503

0.40
0.30

AU

0.20
0.10
0.00
-0.10
-0.20

0.00

2.00

4.00

6.00

8.00

10.00

12.00
Minutes

14.00

16.00

18.00

20.00

22.00

24.00

Results and analysis:
1

Retention Time
10.503

Area
536682

% Area
100.00

Height
49875

Figure A52. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK using a linear
gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.
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Sequence: FITC-NH2-AHx-D-(KLAKLAK)2-AK
Solvent: 2to80 MeCN (0.1%FA) over 17 min
Detection: PDA 220nm
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Figure A53. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK using a linear
gradient 2-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.
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Sequence: Purified Crude D-(KLAKLAK)2-AK-Nucleolipid
Solvent: 2to80 MeOH (0.1%FA) over 17 min
Detection: PDA 260nm
Note: After 17min, column contains impurities that are also found in the blank that has not been integrated.
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Figure A54. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-Hexadecylamine
nucleolipid using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C
at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: Purified Crude D-(KLAKLAK)2-AK-Nucleolipid
Solvent: 2to80 MeCN (0.1%FA) over 17 min
Detection: PDA 220nm
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Figure A55. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-hexadecylamine
nucleolipid using a linear gradient 2-80% MeCN/H2O (0.1% FA) over 17 min using a Waters
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C
at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: Pure FITC-D-(KLAKLAK)2-AK-Nucleolipid (FITC isomer used)
Solvent: 20to80 MeOH (0.1%FA) over 17 min
Detection: PDA 220 nm
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Figure A56. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AKhexadecylamine nucleolipid using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: Pure FITC-D-(KLAKLAK)2-AK-Nucleolipid (FITC isomer used)
Solvent: 20to80 MeCN (0.1%FA) over 17 min
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Figure A57. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AKhexadecylamine nucleolipid using a linear gradient 2-80% MeCN/H2O (0.1% FA) over 17 min
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm.
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Sequence: Pure D-(KLAKLAK)2-AK-Palmitamide
Solvent: 20to80 MeCN (0.1%FA) over 17 min
Detection: PDA 220 nm
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Figure A58. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-Palmitamide using a
linear gradient 20-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.
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Sequence: D-(KLAKLAK)2-AK-Palmitamide
Solvent: 20to80 MeOH (0.1%FA) over 17 min
Detection: PDA 220 nm

Results and analysis:
1

Retention Time
17.650

Area
7418305

% Area
100.00

Figure A59. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-Palmitamide using a
linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.

185

Sequence: FITC-D-(KLAKLAK)2-AK-Palmitamide
Solvent: 20to80 MeOH (0.1%FA) over 17 min
Detection: PDA 495 nm
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Figure A60. RP-HPLC analysis of purified FITC-D-(KLAKLAK)2-AK-Palmitamide using a
linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.
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Sequence: FITC-D-(KLAKLAK)2-AK-Palmitamide
Solvent: 20to80 MeCN (0.1%FA) over 17 min
Detection: PDA 495 nm
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Figure A61. RP-HPLC analysis of purified FITC-D-(KLAKLAK)2-AK-Palmitamide using a
linear gradient 20-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0
mL/min with detection at 220 nm.
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Figure A62. 1H-NMR spectrum of 3.6
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Figure A63. 13C-NMR spectrum of 3.6
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Figure A64. 1H-NMR spectrum of 3.7
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Figure A65. 13C-NMR spectrum of 3.7
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Figure A66. 1H-NMR spectrum of 3.8
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Figure A67. 13C-NMR spectrum of 3.8
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Figure A68. 1H-NMR spectrum of 3.9
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Figure A69. 13C-NMR spectrum of 3.9
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Figure A70. 1H-NMR spectrum of 3.10
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Figure A71. 13C-NMR spectrum of 3.10
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Figure A72. 1H-NMR spectrum of 3.11
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Figure A73. 13C-NMR spectrum of 3.11
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Figure A74. 1H-NMR spectrum of 3.12
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Figure A75. 13C-NMR spectrum of 3.12
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Figure A76. 1H-NMR spectrum of 3.13
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Figure A77. 13C-NMR spectrum of 3.13
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Figure A78. 1H-NMR spectrum of 3.14
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Figure A79. 13C-NMR spectrum of 3.14
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Figure A80. 1H-NMR spectrum of 3.15
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Figure A81. 13C-NMR spectrum of 3.15
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Figure A82. 1H-NMR spectrum of 3.16
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Figure A83. 13C-NMR spectrum of 3,16
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Figure A84. 1H-NMR spectrum of 3.17
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Figure A85. 13C-NMR spectrum of 3.17
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Figure A86. 1H-NMR spectrum of 3.18
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Figure A87. 13C-NMR spectrum of 3.18
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Figure A88. 1H-NMR spectrum of 3.19
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Figure A89. 13C-NMR spectrum of 3.19
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Figure A90. 1H-NMR spectrum of 3.20
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Figure A91. 13C-NMR spectrum of 3.20
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